Molecular Determinants of Microvascular Dysfunction in Hypertensive Pregnancy and Preeclampsia

Wentao Yu, **Wei Gao**, **Dan Rong**, **Zhixian Wu**, and **Raouf A. Khalil**

Vascular Surgery Research Laboratories, Division of Vascular and Endovascular Surgery, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA 02115, USA

Abstract

Preeclampsia is a pregnancy-related disorder characterized by hypertension and often fetal intrauterine growth restriction, but the underlying mechanisms are unclear. Defective placentation and apoptosis of invasive cytotrophoblasts cause inadequate remodeling of spiral arteries, placental ischemia and reduced uterine perfusion pressure (RUPP). RUPP causes imbalance between the anti-angiogenic factors soluble fms-like tyrosine kinase-1 and soluble endoglin and the pro-angiogenic vascular endothelial growth factor and placental growth factor, and stimulates the release of proinflammatory cytokines, hypoxia-inducible factor, reactive oxygen species, and angiotensin AT_1 receptor agonistic autoantibodies. These circulating factors target the vascular endothelium, smooth muscle and various components of the extracellular matrix. Generalized endotheliosis in systemic, renal, cerebral and hepatic vessels causes decreases in endothelium-derived vasodilators such as nitric oxide, prostacyclin and hyperpolarization factor, and increases in vasoconstrictors such as endothelin-1 and thromboxane A2. Enhanced mechanisms of vascular smooth muscle contraction such as intracellular Ca^{2+}, protein kinase C and Rho-kinase cause further increases in vasoconstriction. Changes in matrix metalloproteinases and extracellular matrix cause inadequate vascular remodeling and increased arterial stiffening, leading to further increases in vascular resistance and hypertension. Therapeutic options are currently limited, but understanding the molecular determinants of microvascular dysfunction could help in the design of new approaches for the prediction and management of preeclampsia.

Keywords

Cytokines; Endothelium; Extracellular Matrix; Growth Factors; Hypertension; Microvessels; Placental Ischemia; Vascular Smooth Muscle

INTRODUCTION

Normal pregnancy is associated with several uteroplacental and hemodynamic changes in order to meet the metabolic demands of the growing fetus. Placental remodeling and trophoblast invasion of spiral arteries maintain adequate uteroplacental perfusion.[1] Also, the

Correspondence and Reprints: Raouf A Khalil, MD, PhD, Harvard Medical School, Brigham and Women's Hospital, Division of Vascular Surgery, 75 Francis Street, Boston, MA 02115, Tel : (617) 525-8530, Fax : (617) 264-5124, raouf_khalil@hms.harvard.edu.

CONFLICT OF INTEREST

None

increases in maternal plasma volume and cardiac output are counterbalanced by systemic vasodilation and decreased vascular resistance, leading to slight decrease in blood pressure (BP).[2,3] These pregnancy-related changes involve marked uteroplacental and vascular remodeling and redistribution of blood flow in different maternal tissues.[4] Matrix metalloproteinases (MMPs) are major regulators of tissue remodeling, and play an important role in the uteroplacental and vascular remodeling during pregnancy.

In 5 to 8% of pregnancies, women may have hypertension in pregnancy (HTN-Preg) in one of four forms: chronic HTN that predates pregnancy, preeclampsia (PE)-eclampsia, chronic HTN with superimposed PE, and nonproteinuric gestational HTN.[5] PE is diagnosed after the 20th week of pregnancy by new onset HTN, and occasional proteinuria, edema, increased platelet aggregation, and fetal intrauterine growth restriction (IUGR).[5] PE may be a part of hemolysis elevated liver enzymes low platelets (HELLP) syndrome. If not treated, PE may progress to eclampsia with severe HTN and convulsions, and could culminate into coma and death, causing an estimated 14% of pregnancy-related maternal deaths.[6]

Although PE is a major cause of maternal and fetal morbidity and mortality, its etiology and pathophysiology are not fully understood. Certain genetic and environmental risk factors are believed to cause inadequate placentation and reduction in uteroplacental perfusion pressure (RUPP), and the resulting placental ischemia/hypoxia causes the release of circulating factors that target the blood vessels (Fig. 1). Because of the difficulty to perform mechanistic studies in pregnant women, animal models of HTN-Preg have been developed. RUPP during late pregnancy in sheep, dog, rabbit and rat has been shown to induce a hypertensive state that closely resembles PE.[7,8] BP is increased, and the litter size and pup weight are decreased in RUPP versus normal pregnant rats.[9,10] Studies have also shown changes in circulating levels of pro-angiogenic and anti-angiogenic factors, proinflammatory cytokines, hypoxia-inducible factor, reactive oxygen species and angiotensin II (AngII) type 1 receptor (AT_1R) agonistic autoantibodies (AT_1-AA) in PE. These circulating factors are believed to target endothelium-derived relaxing and contracting factors and the mechanisms of vascular smooth muscle (VSM) contraction leading to increased vasoconstriction. Also, abnormalities in MMPs could affect extracellular matrix (ECM) and lead to inadequate vascular remodeling. Changes in systemic vessels cause generalized vascular dysfunction and HTN, while changes in renal glomeruli cause glomerular endotheliosis, increased glomerular permeability and proteinuria. Also, changes in cerebral vessels cause cerebral edema and seizures, while changes in hepatic vessels could lead to HELLP syndrome.[5,11]

In this review, we will discuss the possible initiating events leading to RUPP, and the various circulating factors released in response to placental ischemia. We will then discuss the different molecular targets in the vascular endothelium, VSM and ECM that could lead to microvascular dysfunction, decreased vascular relaxation, increased vasoconstriction, aberrant vascular remodeling, and HTN. Throughout the review we will briefly define the factor involved, and describe the levels during normal pregnancy followed by the changes in human PE and experimental HTN-Preg. We will then discuss how identifying the molecular determinant of microvascular dysfunction could help design new approaches in the prediction and management of PE.

Defective Placentation and Uteroplacental Ischemia in PE

During early pregnancy, the placenta is developed as a maternal-fetal interface through several biological processes including vasculogenesis, angiogenesis, and trophoblast invasion and remodeling of spiral arteries. Vasculogenesis is the development of *de novo* blood vessels from endothelial progenitor cells and occurs ~18–35 days after conception in humans. Angiogenesis is the sprouting of new blood vessels from preexisting vessels and is regulated by the coordinated actions of pro-angiogenic factors and the invasive capability of trophoblast cells.[12] Healthy pregnancy requires adequate placental vascularization. During the first trimester, the placental extravillous trophoblasts invade deep into the maternal decidua up to one-third of the myometrium, progressively invading the spiral arteries, replacing endothelial cells and VSM, and substituting the elastic tissue with fibrinoid material.[13] This causes gradual dilation and transformation of the spiral arteries from low-capacity high-resistance to high-capacity low-resistance vessels, thus ensuring sufficient blood and nutrient supply to the developing fetus.

The symptoms of PE remit after delivery of the baby and placenta, implicating the placenta as a central culprit in the disorder. Defective placentation, RUPP and placental ischemia/hypoxia are important initiating events in PE.[8,14] Predisposing genetic, demographic and environmental factors could affect placental development. Defective placentation could be caused by abnormal immune responses and accumulation of natural killer (NK) cells and macrophages, apoptosis of cytotrophoblasts, and abnormal expression of integrins and MMPs, leading to shallow trophoblast invasion and poor remodeling of spiral arteries.

Predisposing genetic, demographic and environmental factors in PE

Mutations in placental genes have been associated with PE, and 31 out of 36 placental genes are downregulated in PE.[15] Susceptibility genes include *ACVR2A* gene on chromosome 2q22 and *STOX1* gene on chromosome 10q22. *STOX1* Y153H polymorphism has been linked to inadequate trophoblast invasion and IUGR, and was detected in families with several generations of women who developed early and severe PE.[16] Also, wild-type female mice crossed with transgenic male mice overexpressing human *STOX1* show PE features including HTN and proteinuria.[17] *FOXP3* is another gene that plays a role in the activation of regulatory T cells (Tregs) and controls the immune response and maternal tolerance during pregnancy. Downregulation or polymorphism in *FOXP3* gene could alter the maternal immune response, reduce maternal tolerance and predispose to PE.[18,19]

Ethnic background, age, maternal lifestyle, pre-pregnancy weight, previous and family history of PE, primiparity, and multiple pregnancy could be risk factors for PE.[20] The rate of PE is higher among African-American (5.2%) than Asian women (3.5%).[21] Very young <16 years or older women >40 years are more prone to PE, and studies in Finland and India support that older women are at higher risk of developing PE.[22,23] The incidence of PE is ~3% in women with normal body mass index (BMI, 18.5–24.9), but increases to 7% in overweight women with BMI 30–34.9 and to 13% in obese women with BMI around 50.[24] Preexisting medical condition such as heart disease, chronic respiratory disorders, diabetes, renal disorders, systemic lupus erythematosus, mental stress, reproductive tract surgery and history of antepartum hemorrhage also increase the risk for PE.[20] The relationship between

age, ethnic background, obesity and other predisposing factors and placental development in the setting of PE should be an important area of investigation.

Immune Responses and Defective Placentation in PE—Pregnancy is a physiological process that poses a challenge to maternal tolerance and the immune response. For healthy pregnancy, the maternal systems must tolerate the semi-allogenic fetus, and likewise, the fetus needs to be protected from rejection by the maternal immune response.[25] PE is associated with augmented immune response and increased pro-inflammatory cytokines TNFα and IL-6. In support, HIV-positive women, who often have suppressed immune response, show lower incidence of hypertensive disorders and PE.[26]

During normal pregnancy, cytotrophoblasts express the major histocompatibility complex molecules HLA-C, HLA-E and HLA-G which interact with their respective inhibitory receptors KIR, CD 94/NKGs and ILT-2 on NK cells. These interactions reduce the activity of NK cells and prevent them from attacking normal placental and fetal tissues.[27] A decrease in HLA-C/KIR interaction would lead to increased activity of NK cells, which attack placental and fetal tissues and lead to PE.[28] Also, healthy pregnancy is associated with moderate activation of the complement system. Increased complement activation products Bb, C3a and C5a have been associated with PE.[29] Also, small subcutaneous vessels from PE women show more neutrophils adherent to the endothelium, which may contribute to endothelial dysfunction.[30] Inhibition of complement activation or depletion of neutrophils decreases BP in RUPP rat model of placental ischemia, supporting a role of complement activation and innate immune response in HTN-Preg.[29,31]

Integrins and Reduced Trophoblast Invasion of Spiral Arteries—Trophoblast invasion and remodeling of the spiral arteries is in part regulated by integrins and other adhesion molecules. Cytotrophoblasts initially express epithelial cell-type adhesion molecules such as integrins α_6/β_4 and α_6/β_1, and E-cadherin. During normal pregnancy cytotrophoblasts become more invasive, and the epithelial cell-type adhesion molecules are replaced by the endothelial-type integrins α_1/β_1 and α_V/β_3; a process known as vascular mimicry or pseudovasculogenesis.[32] These phenotypic changes in integrins may be impaired during placental hypoxia and PE. Hypoxia increases expression of integrin α5 and fibronectin and decreases expression of integrin α1.[33] Abnormal expression of epithelial cell-type adhesion molecules and apoptosis of cytotrophoblasts cause limited invasion of spiral arteries, placental ischemia and RUPP.[32,34] Ezrin, an integrin involved in cell adhesion, organization and migration, is downregulated in syncytiotrophoblast microvesicles from PE women, resulting in reduced invasiveness of cytotrophoblasts, shallow placentation and decreased vascularization of the placenta.[35] The decreased trophoblast invasion and replacement of vascular cells also leads to retention of VSM cells in the spiral arteries, causing more vasoconstriction and placental ischemia.[36]

Endothelial intracellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) promote leukocyte migration and adhesion to the endothelium. Also, soluble ICAM-1 (sICAM-1) in the plasma could function as a regulatory molecule of ICAM-1/2-integrin interaction. Endothelial ICAM-1 and VCAM-1 are downregulated during normal pregnancy, thus minimizing leukocyte adhesion to endothelial cells, and

maintaining patency and blood flow in the spiral arteries. In contrast, plasma levels of sICAM-1 and soluble VCAM-1 (sVCAM-1) are increased in PE, indicating endothelial cell dysfunction and increased endothelial ICAM-1 and VCAM-1, which would increase leukocyte adhesion to endothelial cells and restrict blood flow in the spiral arteries.[37,38]

PE is associated with increased placental expression of microRNA miRNA-125b-1–3p which reduces the expression of S1PR1, a G-protein coupled receptor that facilitates invasion of human trophoblasts.[39] PE is also associated with increased expression of placental miRNA-517a/b and miRNA-517c, which may contribute to the decreased trophoblast invasion of extravillous trophoblasts under hypoxic conditions.[40]

MMPs, Abnormal Placentation, and Placental Ischemia

MMPs are zinc-dependent proteases that play a role in tissue remodeling.[41,42] MMPs include collagenases, gelatinases, stromelysins, matrilysins, membrane-type MMPs, and other MMPs.[43] MMPs play a role in endometrial tissue remodeling during the estrous cycle and menstrual cycle, and the uterine and vascular remodeling during pregnancy.[44,45] Trophoblast invasion into the decidual stroma requires degradation of ECM proteins by MMPs. MMP-2 (gelatinase A) and MMP-9 (gelatinase B) are abundantly expressed in invading extravillous trophoblasts.[46,47] Also, epidermal growth factor (EGF)–mediated trophoblast invasion is associated with increased expression of MMP-2 and MMP-9.[48] MMP-2 is the main MMP in the umbilical cord[5], and serum MMP-9 level is elevated in normal pregnancy.[41] The pregnancy-related increase in MMPs may be caused by estrogen and progesterone. Estrogen enhances the release of MMP-2 from human VSM cells.[49] Also, MMP-2 and MMP-9 are increased in the uterus and aorta of pregnant rats, and estrogen and progesterone enhance MMP-2 and MMP-9 expression in the aorta of virgin rats.[50]

The role of MMPs in trophoblast invasion of spiral arteries is supported by the observation that in first trimester trophoblasts, suppression of MMP-9 inhibits the invasive capability of trophoblasts.[51] Also, MMP-9 ablation in MMP-9 knockout mice shows a phenotype that mimics PE possibly due to impaired trophoblast invasion.[52] Genetic polymorphisms in MMP-2 and MMP-9 transcription have been described in PE, and decreased MMP-9 levels have been observed in PE compared with normal placenta.[53] In PE, increased expression of miRNA-519d-3p and miRNA-204 could target MMP-2 and MMP-9 and decrease trophoblast invasion of spiral arteries.[51,54] These observations suggest a relationship between decreased MMP-2 and MMP-9 and impaired trophoblast invasion in PE. However, measurements of plasma MMP levels have not been consistent in PE, with some studies showing an increase in MMP-2 and MMP-9,[55] while other studies showing a decrease in MMP-9,[41] making it important to further measure MMPs in the plasma, placenta and other tissues of PE women and animal models of HTN-Preg.

We have examined whether alteration of MMP expression/activity is a potential mechanism in the uteroplacental and vascular remodeling in animal models of HTN-Preg. We examined the specific changes in three important tissues during pregnancy; the uterus which undergoes remodeling to accommodate the growing fetus, the placenta which provides nutrient supply to the developing fetus, and the aorta for the vascular changes in the maternal circulation. The uterus, placenta, and aortic tissue weight was reduced in RUPP versus normal pregnant

rats. Also, histological morphometry showed reduction in uterine, placental and aortic cross-sectional area in RUPP versus normal pregnant rats, supporting growth-restrictive remodeling in RUPP rats.[42] Western blots, gelatin zymography and immunohistochemistry revealed abundant MMP-2 and MMP-9 in tissues of normal pregnant rats.[50] MMPs immunostaining was prominent in the aortic media, consistent with reports that VSMCs are a major source of MMPs.[56,57] The levels of MMP-2 and MMP-9 were reduced in uterus, placenta and aorta of RUPP versus normal pregnant rats. The decreases in MMP levels, in parallel with the decreases in uterine, placental, and aortic tissue weight and cross-sectional area suggest a role for reduced MMP-2 and MMP-9 in growth-restrictive remodeling in tissues of RUPP rats.[42]

Other MMPs may also be involved in uterine and vascular remodeling in PE. The collagenase MMP-1 is expressed in cytotrophoblasts and syncytiotrophoblasts of the placenta and decidua and may play a role in trophoblast invasion. Some studies have shown low levels of MMP-1 in umbilical cord blood, placenta and decidua of PE versus normal pregnant women.[58] Other studies suggest a role of MMP-1 in the pathogenesis of PE.[59] Also, the matrilysin MMP-7 could play a role in endometrial tissue remodeling during the menstrual cycle and pregnancy.[60] Cytotrophoblasts and VSM also release MMP-12, which could mediate elastolysis and remodeling of spiral arteries.[61] Also, some MMPs cleave other pro-MMPs, and MT1-MMP is a key activator of proMMP-2.[62] MMP activity could also be influenced by tissue inhibitors of metalloproteases (TIMPs) and other MMP modulators.[62] For instance, TIMP-2 or specific MMP-2 blocking antibody inhibits cytotrophoblast invasion *in vitro*.[47] Also extracellular MMP inducer (EMMPRIN, CD147, Basigin) is a widely expressed membrane protein of the immunoglobulin superfamily,[63] that has been implicated in tissue remodeling, cancer, and heart failure.[50] EMMPRIN stimulates the production of MMP-1, MMP-2, MMP-3, and MMP-9, and regulates MMPs in endothelial cells and tumors.[64] We have shown that EMMPRIN expression is increased in the aorta of pregnant compared with virgin rats as well as in the aorta of virgin rats treated with estrogen and progesterone. Also, the sex hormone-induced increases in aortic MMP-2 and MMP-9 were blocked by EMMPRIN neutralizing antibody, supporting a role of EMMPRIN in the increases in vascular MMPs during pregnancy.[50]

Circulating Bioactive Factors in PE

Placental hypoxia/ischemia is believed to trigger the release of several bioactive factors including the antiangiogenic factors sFlt-1 and sEng, pro-inflammatory cytokines such as TNFα and IL-6, HIF, ROS and AT_1-AA (Fig. 1).[65–68] These factors could target uteroplacental and vascular MMPs causing further vasoconstriction of spiral arteries and placental ischemia, as well as the vascular endothelium, VSM and ECM in the systemic circulation leading to generalized vasoconstriction and HTN-Preg.[11]

Pro-angiogenic and Anti-angiogenic Factors in PE

Vascular Endothelial Growth Factor (VEGF)—The *VEGF* gene is located on chromosome 6p21.3, and consists of 8 exons involved in the expression of a family of growth factors including VEGF-A, VEGF-B, VEGF-C, VEGF-D, and PlGF.[69] VEGF-A, VEGF-B and PlGF bind to tyrosine kinase receptor Flt-1 (VEGFR-1). VEGF-A binds to

VEGFR-2 (Flk-1 or KDR) to promote the development of the placental vasculature.[69] VEGF regulates endothelial cell proliferation, angiogenesis and vascular permeability.[69] In endothelial cells, VEGF increases $[Ca^{2+}]_i$, Ca^{2+}/calmodulin, endothelial nitric oxide synthase (eNOS) activity, and prostacyclin (PGI_2).[70,71] VEGF also stimulates Ca^{2+}-independent generation of NO by promoting Akt activation and eNOS Ser^{1177} phosphorylation in human umbilical vein endothelial cells (HUVECs).[72]

Some studies show an increase in circulating VEGF in PE.[73–75] Also, villous explants from PE women produce greater amounts of VEGF than those form normal pregnant women.[76] It is likely that the severe vasoconstriction in PE would increase vascular shear-stress, and in turn increase circulating VEGF.[20] Other studies have shown a decrease or unchanged serum levels of VEGF in PE.[77,78] Women with the T allele of VEGF 936C/T have lower levels of VEGF and a higher risk of PE than women with VEGF 936C/C.[79] Plasma VEGF levels are decreased in RUPP rat model of HTN-Preg,[8] although as with human villous explants, placenta from RUPP rats show greater VEGF production.[80] The differences in the results may be related to the method of VEGF measurement.

A decrease in VEGF may also play a role in the glomerular endotheliosis and proteinuria in PE. VEGF is synthesized constitutively by podocytes in the glomerulus where it maintains endothelial cell health and induces the formation of fenestrae. Endotheliosis and loss of fenestrae have been detected in genetic glomerular VEGF deficiency.[81] Also, in clinical cancer trials the use of VEGF neutralizing antibodies is associated with proteinuria.[82] In mice, infusion of VEGF antibodies leads to glomerular endotheliosis and proteinuria.[83] Also, mice lacking one VEGF allele in renal podocytes develop a renal pathology similar to that in PE. Importantly, infusion of VEGF ameliorates the renal lesions, glomerulonephritis and thrombotic microangiopathy in RUPP rats, suggesting potential benefits of pro-angiogenic factors in the glomerular endotheliosis associated with HTN-Preg.[84,85]

MMPs induce the release of growth factors by cleaving the growth factor-binding proteins or matrix molecules. MMPs may also be regulated by growth factors.[86] MMPs may mediate the angiogenic effects of VEGF by virtue of their proteolytic activity and other mechanisms including helping to detach pericytes from the vessels undergoing angiogenesis, releasing ECM-bound angiogenic growth factors, exposing cryptic pro-angiogenic integrin binding sites in ECM, generating pro-migratory ECM component fragments, and cleaving endothelial cell-cell adhesions.[87] Interestingly, VEGF increases the expression of MMP-1, MMP-3, MMP-7, MMP-8, MMP-9, MMP-10, MMP-13, and MMP-19 in HUVECs, and induces MMP-10 expression via PI_3K and MAPK pathways.[88] The interaction between MMPs and VEGF in the setting of uteroplacental and vascular remodeling in normal pregnancy and PE should be further examined.

Placental Growth Factor (PlGF)—PlGF is a pro-angiogenic factor that binds to VEGFR-1 and enhances the angiogenic effects of VEGF.[89] PlGF has only 1/10th the affinity of VEGF for VEGFR-1, but its levels are ~40 times higher than those of VEGF during normal pregnancy. PIGF promotes endothelial cell growth, placental vasculogenesis, and vasodilation of uterine vessels.[11]

Plasma PlGF levels are low in non-pregnant women (~44 pg/mL), and markedly increase during normal pregnancy.[89] PlGF levels are ~353 pg/mL during gestational weeks 21 and 22, rising steadily to ~574 pg/mL after gestational weeks 29 and 30.[90] Circulating PlGF levels decrease in PE,[73,91] and the decrease is more apparent in early than late PE.[92] PlGF has four alternatively spliced mRNA forms (PlGF 1–4), and its predominant isoform PlGF-1 is downregulated in PE.[93] Circulating levels of PlGF are also decreased in RUPP and deoxycorticosterone acetate (DOCA)-salt hypertensive rats.[8,94]

In addition to its growth promoting effects, PlGF promotes vasodilation via VEGFR-1 and endothelium-derived hyperpolarizing factor (EDHF)-mediated activation of small conductance Ca^{2+}-activated K^+ channels (SK_{Ca}).[95,96] In small mesenteric arteries of pregnant rats treated with L-NAME and indomethacin, a second exposure to PlGF produces greater vasodilation and greater reduction in VSM $[Ca^{2+}]_i$ than the first PlGF application. VEGF and PlGF may promote VEGFR-1 dimerization, and the initial exposure to PlGF may facilitate the formation of receptor homodimers and their submembrane signaling, leading to augmented vasodilator responses to repeated PlGF stimulation.[96] A decrease in the levels of PlGF may be partly responsible for the decreased vasodilator responses in PE.

Soluble fms-like Tyrosine Kinase-1 (sFlt-1)—sFlt-1 (sVEGFR-1) is an anti-angiogenic factor expressed as an alternatively spliced variant of VEGFR-1 that lacks both the transmembrane and cytoplasmic domains. sFlt-1 binds VEGF and PlGF and blocks their angiogenic effects on VEGFR. sFlt-1 may also form a heterodimer with the surface membrane VEGFR-1 and inhibit its post-receptor signaling actions.[97] Trophoblasts express sFlt-1 mRNA. sFlt-1 levels are ~0.15 ng/mL in non-pregnant women and increase to ~1.5 ng/mL in normal pregnant women.[11] sFlt-1 levels are largely stable in normal pregnant women, and show an increase after gestational week 36. Throughout the third trimester, an increase in sFlt-1 is associated with some reduction in VEGF and PlGF levels. PE women show imbalance between sFlt-1, VEGF and PlGF.[77,92] The *sFlt-1* gene has a gene locus on chromosome 13q12. In women with trisomy 13, an extra copy of the *sFlt-1* gene is associated with increased circulating sFlt-1, reduced PlGF and increased risk of PE.[98] Studies have shown higher circulating levels of sFlt-1 in early and late PE.[91,92] Serum sFlt-1 is also higher in women with previous PE (~0.5 ng/mL) than in women with previous normal pregnancy (~0.3 ng/mL), and the increases can be detected even 6 months after delivery.[99] sFlt-1 levels are also greater in villous explants from PE compared with normal pregnant women.[76]

Placental ischemia/hypoxia may trigger the production of sFlt-1. During placental hypoxia, HIF-1 may bind to the promoter region of *flt-1* gene leading to upregulation of sFlt-1.[76,77] In extravillous trophoblasts, overexpression of miR-517a/b and miR-517c increase the expression of TNFSF15, a cytokine that promotes Flt-1 splicing, and increases the production of sFlt-1.[40] sFlt-1 e15a, a splice variant of sFlt-1 and the most abundant form released by the placenta, binds VEGF and in turn decreases endothelial cell migration, invasion, and tube formation. sFlt-1 e15a is expressed in syncytiotrophoblasts and its serum levels are 10-fold higher in PE than normal pregnant women.[100]

Because of the increased levels of sFlt-1, a 53% decrease in VEGF/sFlt-1 ratio and a 70% decrease in PlGF/sFlt-1 ratio have been observed in PE placenta.[76] The circulating sFlt-1/PlGF ratio is higher in PE than normal pregnant women from second trimester onwards and may serve as a predictor of the onset of PE,[92] However, some studies suggest that the circulating sFlt-1/PlGF ratio could be lower in late versus early PE.[92,101] Circulating sFlt-1 levels and sFlt-1/PlGF ratio are higher in twin than singleton pregnancies, and the difference is likely related to the greater placental mass in twin pregnancies.[102,103] The proportionate increases in sFlt-1 and sFlt-1/PlGF ratio in twin versus singleton pregnancies support the concept that the placenta is a major source of these factors. Angiogenic imbalance may affect endothelin-1 (ET-1) levels. PE women with sFlt-1/PlGF ratio >85 have higher levels of ET-1 than women with sFlt-1/PlGF ratio <85.[104] Importantly, extracorporeal removal of circulating sFlt-1 from PE patients decreases sFlt-1/PlGF ratio, improves symptoms and prolongs pregnancy,[105] further supporting a role of sFlt-1 in PE.

RUPP rats show increases in plasma and placental levels of sFlt-1 and plasma sFlt-1/PlGF ratio.[8,106] Other animal models of HTN-Preg show either increased or little change in circulating sFlt-1 levels.[94,107–111] Importantly, Infusion of exogenous sFlt-1 or adenoviral overexpression of sFlt-1 in pregnant rats causes increases in BP, decreased plasma VEGF, proteinuria, and glomerular endotheliosis with occlusion of renal capillaries and focal fibrin deposition in glomerular cells.[77,112] Also, mice treated with sFlt-1 show increased vascular response to ET-1.[113] Treatment of endothelial cells with plasma of PE patients decreases angiogenesis, and removal of sFlt-1 or treatment with VEGF or a sFlt-1 antibody restores endothelial cell angiogenesis.[76]

Of note, VEGF through an action on VEGFR-2 stimulates the production of sFlt-1 in human placental explants.[114] This feedback modulation of VEGF by sFlt-1 may represent a local protective mechanism at the maternal-fetal interface to control VEGF levels and prevent damage to the placenta or fetus by excess VEGF during normal pregnancy,[114] and this VEGF-sFlt-1 feedback mechanism may be altered in PE.

Some studies suggest that sFlt-1-induced inhibition of VEGFR-2 could decrease endothelial VEGF production and MMP-2 and MMP-9 expression/activity.[115] In mouse model of abdominal aortic aneurysm treatment with sFlt-1 reduces aneurysm size and attenuates MMP-2 and MMP-9 activity in peri-aortic tissue.[116] Also, our recent studies have supported a role of sFlt-1 as a potential upstream mechanism to decrease MMPs in HTN-Preg.[42] We found that sFlt-1 reduced MMPs in uterine, placental and vascular tissues of normal pregnant rats, while VEGF reversed the sFlt-1 induced decreases in MMPs in tissues of normal pregnant rats and increased MMPs levels in tissues of RUPP rats to levels similar to those in normal pregnant rats. These observations are consistent with reports that infusion of VEGF reduces BP in RUPP rats.[117]

Soluble Endoglin (sEng)—Transforming growth factor-β1 (TGF-β1) binds to TGF receptor and induces proliferation and migration of endothelial cells.[69] Endoglin (Eng) is a co-receptor for TGF-β1 and TGF-β3 that is highly expressed on cell membrane of endothelial cells and syncytiotrophoblasts, where it mediates proliferation of angiogenic endothelial cells and trophoblasts.[118] Mutations in *Eng* gene are associated with loss of

capillaries, arterio-venous malformations, and hereditary hemorrhagic telangiectasia.[119] sEng is an anti-angiogenic protein that binds TGF-β1 and prevents it from binding to its natural angiogenic receptor, and thereby inhibits TGF-β1-induced eNOS activation and vasodilation.[69] Hypoxia induces the release of sEng. In placental extracts, exposure to hypoxia increases the expression of sEng.[120]

Serum levels of sEng are barely detectable in non-pregnant women and are much lower in normal pregnant women.[121] The levels of sEng are 3-, 5- and 10-fold higher in women with mild PE, severe PE and HELLP syndrome, respectively, compared with gestational age–matched control pregnant women.[121] Serum levels of sEng may be increased in early and late PE.[122,123] However, one study showed an increase in sEng levels at gestational weeks 10–17 in women who developed early PE, but not in those who developed late PE.[101]

In RUPP rat model of HTN-Preg, sEng levels are increased in the serum and placenta, and serum TGF-β levels are decreased.[67] However, sEng levels did not show detectable change in DOCA-salt or L-NAME treated rat models of HTN-Preg.[94,107] It is likely that sEng acts in concert with sFlt-1 to aggravate vascular permeability, proteinuria, IUGR and HTN.[121] In support, pregnant rats infused with both sEng and sFlt-1 show HELLP syndrome-like characteristics.[124] In cultured HUVECs, sEng impairs endothelial formation.[121] Whether sEng targets MMPs and affects uteroplacental and vascular remodeling in HTN-Preg is unclear. Of note, MMP-14 cleaves Eng, the TGF-β co-receptor, and inhibits its angiogenic effects,[125] and these effects may play a role in PE.

Cytokines, TNFα, and Interleukins

In PE, defective trophoblast invasion and decreased uteroplacental blood flow result in periods of ischemia/reperfusion. During placental reperfusion injury, reestablished blood flow causes the release of the pro-inflammatory cytokines TNFα and interleukins (ILs).[5,11,25,126] The circulating levels of TNFα are greater in PE than normal pregnant women,[127,128] although the placental levels of TNFα may not be different in PE versus normal pregnancy.[129] LIGHT, or TNF superfamily member 14, is also increased in PE and may contribute to placental ischemia.[130] The plasma levels and CD4+T cell production of TNFα are increased in RUPP versus normal pregnant rats.[126,131,132] Infusion of TNFα causes HTN and proteinuria in late pregnant mice, rats, and baboons.[110,111,133] Similarly, infusion of the TNF superfamily member LIGHT in pregnant mice increases BP, proteinuria, and the expression of ET-1 and sFlt-1.[130] TNFα may work in concert with IL-6 to increase ET-1 levels and cause HTN in RUPP rats.[126] TNFα may also function in synergy with sFlt-1 to promote a pro-inflammatory and antiangiogenic state. Treatment of HUVECs with both TNFα and sFlt-1 causes an increase in the adhesion molecules ICAM and VCAM and promotes the release of markers of endothelial dysfunction such as ET-1 and von Willebrand factor.[72] In support of a role of TNFα in HTN-Preg, blockade of TNFα with the TNFα decoy receptor etanercept reduces BP in RUPP rats. Also, treatment of HUVECs with serum from RUPP rats treated with the TNFα blocker etanercept produces less ET-1 than serum from nontreated RUPP rats.[126]

TNFα modulates the immune response. TNF-α increases vascular permeability, fibroblast proliferation and lymphocyte activation, and promotes the production of IL-6 and IL-8.

TNFα downregulates eNOS and mitochondrial biogenesis, leading to mitochondrial dysfunction, oxidative stress and increased ROS production.[134] TNFα also alters the expression of adhesion molecules in placental vessels.[126] and MMP production in PE.[135]

IL-6 is another cytokine that is elevated in PE.[123,127] RUPP rats show increased plasma levels and higher CD4+T cell production of IL-6.[131,132] Chronic infusion of IL-6 in pregnant rats causes HTN, proteinuria,[136] enhanced vascular contraction and reduced endothelium-dependent relaxation.[65] IL-6 promotes dimerization of the surface receptor GP-130 on endothelial cells leading to abnormal cell signaling and vascular dysfunction. IL-6 also increases vascular permeability by disrupting the tight junctions in endothelial cells.[137]

IL-1β could also promote the inflammatory response and disrupt endothelial function in PE. Monocyte production of IL-1β is greater in PE than normal pregnant women.[138]

IL-10 is an anti-inflammatory cytokine whose levels are reduced in the plasma and placenta of PE women and plasma of RUPP rats.[128,129,132] Also, in placental trophoblasts, exposure to hypoxia increases pro-inflammatory cytokines and decreases IL-10.[139]

The source of pro-inflammatory cytokine in PE is mostly in the maternal circulation. Monocytes and macrophages are the main reservoirs of cytokines and are the first cells to be activated in nonspecific immune response.[140] Monocytes produce more TNFα and IL-6 when treated with plasma from PE than normal pregnant women.[140] IL-10 may regulate the monocytes and the inflammatory response during normal pregnancy by controlling TNFα and IL-1β gene expression,[138] and the IL-10-mediated regulatory effects appear to be lost in PE. Interestingly, uric acid stimulates monocytes to release cytokines, and hyperuricemia is often observed in PE patients. Also, monocytes from PE patients with high levels of uric acid produce more TNFα and IL-1β than monocytes from normal pregnant women.[138] MMPs may also promote the release of cytokines in PE.[141]

Hypoxia-Inducible Factor (HIF)

HIF is a transcriptional factor that plays a role in the physiologic responses to hypoxia. HIF-1 is a heterodimer consisting of an oxygen-regulated HIF-1α and HIF-2α subunits and a constitutively expressed HIF-1β subunit. While hypoxia is an important inducer of HIF, *de novo* synthesis of HIF-1α may occur in response to non-hypoxic stimuli such as pro-inflammatory factors. TNFα upregulates HIF-1α mRNA expression.[111] Also, a large number of genes are regulated by HIF-1 including VEGF, leptin, TGF-β3, and NOS. DNA microarray analysis in arterial endothelial cells have shown that more than 2% of human genes are regulated directly or indirectly by HIF-1.[5]

HIF expression increases during pregnancy, likely due to increased estrogen and progesterone. Estrogen stimulates uterine HIF-2α, and progesterone upregulates uterine HIF-1α expression.[142] HIF shows further increase in PE.[143] Circulating HIF-1α levels are increased in PE compared with normal pregnant women.[144] HIF-1α may contribute to the pathogenesis of PE by upregulating the anti-angiogenic factors sFlt-1 and sEng, binding to ET-1 gene and changing ET-1 mRNA expression, reducing the trophoblast invasion capability, and inducing AngII-converting enzyme (ACE) expression in the lungs and kidney

and AngII production.[5,145] In support, HIF-1α increases sFlt-1 in human villous trophoblasts.[146] Placental levels of HIF-1α are elevated in RUPP rat model of HTN-Preg.[67] Also, downregulation of HIF-1α mRNA using siRNA reverses the increases in BP, proteinuria, renal damage and serum levels of sFlt-1 in mice models of HTN-Preg.[146]

In addition to the role of HIF in oxygen homeostasis and its regulation by oxygen,[147] cytokines, hormones, metallic ions and mechanical stretch induce HIF expression.[147,148] Prolonged mechanical stretch increases HIF-1α and HIF-2α mRNA expression and protein levels in skeletal muscle fibers.[149,150] Also, upregulation of HIF-1α has been observed in rat cardiac myocytes, aortic VSM cells and fibroblasts exposed to mechanical stretch.[151–153] HIF-1α mRNA is upregulated in VSM cells subjected to cyclic stretch for 4 hours.[151] Also, HIF-1α protein is increased in fibroblasts subjected to cyclic stretch for 24 hours.[153] The mechanisms via which mechanical stretch upregulate HIF may involve PI_3K and MAPK. [148,149,151] Studies have suggested that HIF regulates the expression of MMP-2 and MMP-9.[154,155] Also, we have shown that mechanical stretch increases HIF-1α expression, and that HIF could increase MMP expression in rat inferior vena cava.[156] Whether HIF functions as a transducing signaling mechanism between vascular mechanical stretch and the expression of MMPs during pregnancy needs to be examined.

Reactive Oxygen Species (ROS)

ROS such as superoxide anion ($O_2^{\bullet-}$), hydrogen peroxide (H_2O_2) and hydroxyl ion (OH^-) contain highly reactive O_2. Normal pregnancy represents a state of oxidative stress caused by increased maternal metabolism and metabolic activity of the placenta. Although generation of ROS is increased during pregnancy,[157] placental production of ROS is normally counterbalanced by antioxidants.[5] In contrast, in PE, defective placentation and decreased uteroplacental vascularization result in periods of placental ischemia/reperfusion and a hypoxic environment that favors oxidative stress.[134] In PE, the levels of antioxidants may be too low to counterbalance the increased ROS production.[158]

Hemeoxygenase (HO) is the rate-limiting enzyme responsible for degradation of heme to biliverdin, free iron and carbon monoxide (CO) in the endoplasmic reticulum. Biliverdin is rapidly reduced to bilirubin, an antioxidant, by the cytosolic enzyme biliverdin reductase. CO is a potent vasodilator with anti-apoptotic properties. HO has two main isoforms, HO-1 and HO-2. HO-2 is a 36 kDa protein constitutively expressed at high levels in the brain, testis and vascular endothelium. HO-1 is an inducible 32 kDa protein that is widely distributed in the body, with high levels in the liver and spleen. HO-1 is induced by its substrate heme and by heavy metals. Stimuli that cause oxidative stress, such as peroxynitrite, modified lipids, hypoxia, hyperoxia, ischemia/reperfusion, hyperthermia and endotoxic shock, up-regulate HO-1 expression.[159] HO-1 via its products inhibits oxidative stress, inflammation and apoptosis.[160] HO-1 deficiency results in endothelial damage as indicated by elevation of thrombomodulin and von Willebrand factor.[161]

Expression of antioxidant enzymes such as HO-1, HO-2, copper/zinc superoxide dismutase, glutathione peroxidase and catalase is decreased in PE. Also, the total antioxidant capacity is lower in serum of PE than normal pregnant women.[162] ROS/antioxidants imbalance leads to lipid peroxidation, increased thromboxane A2 (TXA_2) and loss of glutathione peroxidase

activity in the placenta.[163] Antioxidant levels were reduced in women who were later diagnosed with early PE,[164] supporting a role of oxidative stress in the pathogenesis of PE. In PE women, reduced brachial artery flow-mediated dilation is associated with decreased plasma levels of the antioxidant ascorbate, and administration of ascorbic acid improves flow-mediated dilation, supporting a relation between oxidative stress and endothelial dysfunction in PE.[165] Also, placental levels of HO-1 are reduced in RUPP compared with normal pregnant rats,[67] supporting a role of ROS in HTN-Preg.

Neutrophils and monocytes are major sources of ROS in PE. Monocytes from PE women produce more H_2O_2 and $O_2^{\bullet-}$ and cause more endothelial cell damage than monocytes from normal pregnant women.[166,167] Neutrophils also produce NO, which can protect cells from the damaging effects of $O_2^{\bullet-}$ during normal pregnancy. However, in PE, excess $O_2^{\bullet-}$ scavenge the NO produced by neutrophils to form peroxynitrite ($ONOO^-$), thus reducing NO bioavailability and causing endothelial cell damage.[167] NADPH oxidase is a membrane-bound enzyme that catalyzes the one-electron reduction of oxygen to $O_2^{\bullet-}$ via NADPH. NADPH oxidase isoform NOX1 is overexpressed in the placenta of PE women.[168] In HUVECs, treatment with serum from PE women increases mRNA expression of the NADPH oxidase subunit gp91^{phox}, and augments $O_2^{\bullet-}$ production.[169] Treatment of HUVECs with PE serum also causes overexpression of iNOS,[169] which produces excess NO and in turn increase ROS and promotes endothelial cell injury. In RUPP rat model of HTN-Preg treatment with iNOS inhibitors decreases BP, aortic levels of ROS and NADPH-dependent production of ROS.[170] Biopterin (BH_4) promotes eNOS dimerization and activity. Hypoxia reduces BH_4 causing eNOS uncoupling, increased ROS production, and decreased NO bioavailability.[171] In DOCA-salt hypertensive rats, supplementation with a BH_4 such as sepiapterin decreases production of $ONOO^-$ and $O_2^{\bullet-}$ and increases NO production.[171]

Other markers of lipid peroxidation and oxidative stress such as malondialdehyde and prostaglandin $F_{2\alpha}$ are increased in serum of PE women at gestational weeks 10–14. This may cause gradual oxidative damage in the placenta, even before overt symptoms of PE.[172] Plasma levels of the oxidative stress marker 8-isoprostane, and total aortic and placental levels of ROS are higher in RUPP than normal pregnant rats.[132,170] In first-trimester villous trophoblasts, excessive oxidative stress affects the expression of miRNAs involved in angiogenesis, apoptosis, immune response and inflammation, and this could be a potential mechanism in PE.[173] MMPs may also contribute to the increases in ROS in PE.[141]

AngII and AT$_1$ Receptor Agonistic Autoantibodies (AT$_1$-AA)

The renin-angiotensin-system (RAS) is involved in the regulation of salt, water, and BP. Normal pregnancy is associated with increased blood volume with little change in BP, raising the possibility that RAS plays a role in PE. In a study to investigate the role of RAS and plasma progesterone levels in HTN-Preg, sequential measurements were made throughout pregnancy in normotensive subjects, HTN-Preg patients in whom HTN became manifest only during pregnancy (PE), and patients with chronic HTN antedating pregnancy. Among the normotensive subjects, plasma renin activity and substrate, and plasma aldosterone and progesterone levels were elevated as early as gestational week 6. Progressive increases were noted in renin substrate, aldosterone and progesterone levels

during pregnancy, but plasma renin activity did not continue to rise. In HTN-Preg groups, plasma levels of renin substrate and progesterone were not different from those in normotensive pregnancy, but plasma renin activity and aldosterone levels were suppressed during the last trimester, likely through secondary effects. RAS suppression did not appear to be due to a decrease in renin substrate levels and a hypothesized deficiency of plasma progesterone was not observed in the hypertensive subjects suggesting that it may not play a permissive role in the development of HTN-Preg.[174] Another prospective longitudinal study explored the relationship between RAS and the development of superimposed PE. In pregnant women with chronic HTN in whom PE did not develop, BP decreased and RAS was stimulated, beginning in the first trimester and continuing throughout pregnancy as in normotensive pregnant women. Plasma estradiol and progesterone levels also increased progressively. In women with chronic HTN in whom PE developed, BP decreased and RAS was stimulated in the first trimester as in the other groups. However, later in pregnancy BP began to rise in the second trimester. Initially RAS remained stimulated, but in the early third trimester, when PE was diagnosed, plasma renin activity and urine aldosterone excretion decreased, and atrial natriuretic factor increased,[175] supporting that RAS is modulated in HTN-Preg and PE.

AngII is an important regulator of water and electrolyte homeostasis and BP. AngII activation of vascular AT_1R promotes vascular growth, inflammation, and vasoconstriction and increases $[Ca^{2+}]_i$ and Rho-kinase activity in VSM. AngII activation of endothelial AT_2R increases eNOS activity and NO production, PGI_2, and vasodilation, and thereby counteracts AngII-induced vasoconstriction. Therefore, while normal pregnancy is associated with increased plasma levels of renin and AngII, the pressor effects of AngII are decreased due to decreased AT_1R and/or increased AT_2R. On the other hand, the dose of AngII required to elicit a 20 mmHg pressor response in the diastolic BP in women at gestational weeks 23–26 was lower in women who subsequently developed PE compared with normal pregnant women who remained normotensive,[176] suggesting an increase in the pressor response to AngII long before overt PE.

AngII levels and AT_1R mRNA expression are increased in chorionic villi and placenta of PE versus normal pregnant women.[177,178] Plasma hemopexin activity increases during normal gestation from week 10 onward, and active hemopexin downregulates AT_1R in human monocytes and endothelial cells, and decreases functional AT_1R and AngII-induced contraction in rat aortic rings. In PE, hemopexin activity may be inhibited resulting in enhanced AT_1R expression and increased vasoconstriction.[179]

AT_1-AA is a bioactive factor that promotes vasoconstriction and VSM growth via AT_1R. Serum levels of AT_1-AA are elevated in PE than normal pregnant women,[109,180] and are further elevated in severe PE and in early versus late PE.[181] AT_1-AA has been linked to increased BP, reduced trophoblast invasion, increased sFlt-1, ROS and cellular Ca^{2+}, activation of coagulation tissue factor and thrombosis, vascular damage in the adrenal glands, and reduced aldosterone secretion in PE.[109,182] AT_1-AA also promotes collagen-induced platelet aggregation, which may contribute to the hypercoagulability in PE.[180] In cultured trophoblasts, stimulation of AT_1R with IgG isolated from PE women causes increases in sFlt-1 levels.[183] In HUVECs, treatment with AT_1-AA isolated from PE women

induces the release of the cell death and necrosis marker lactate dehydrogenase,[184] suggesting that AT_1-AA causes endothelial cell damage and necrosis. Also, in HUVECs, AT_1-AA induces the activity of caspase-3 and caspase-8, suggesting that it promotes endothelial cell apoptosis.[184] Circulating levels of AT_1-AA are also increased in RUPP compared with normal pregnant rats.[185,186] Infusion of AT_1-AA in pregnant mice causes some of the manifestations of PE including increased BP, proteinuria and plasma sFlt-1 levels.[109] Also, infusion of AT_1-AA in pregnant rats increases ET-1 levels 4-fold in the placenta and 11-fold in the renal cortex.[187] Endothelium-dependent acetylcholine (ACh)-induced vasodilation is reduced in the renal interlobar arteries of pregnant rats infused with AT1-AA, suggesting a link between AT1-AA and renal endothelial dysfunction in HTN-Preg. The impaired ACh-induced vasodilation in AT1-AA infused pregnant rats is reversed by an ET_AR antagonist, suggesting an interplay between AngII and ET-1 in the setting of endothelial dysfunction and HTN-Preg.[188] While the mechanisms causing the release of AT_1-AA in PE are not understood, plasma levels of AT_1-AA are increased in pregnant rats infused with TNFα, suggesting cytokine-mediated pathways.[186]

Extracellular Vesicles (EVs) in PE

Extracellular vesicles (EVs) are lipid-bilayer structures that are released from cells into the extracellular environment. They contain proteins, miRNA, growth and apoptotic factors, and other regulatory components to induce cell-to-cell communication and signaling throughout the body. EVs are released under normal and pathological conditions, and multiple EV types can be produced from different cells, including red blood cells, fibroblasts, endothelial cells, and trophoblasts. After secretion from cells, EVs modify the activity of adjacent cells or travel to regions distal to the site of release in several body fluids. In PE, impaired placental function with placental apoptosis and necrosis causes increased release of microvesicles and nanovesicles. These exosomes contain proteins, miRNA, DNA, RNA; as well the lipids comprising the vesicular wall. EVs (including exosomes) originating from placental explant and cells promote pro-inflammatory cytokines production and endothelial dysfunction, and may be involved in different stages of PE.[189]

Vascular Dysfunction in HTN-Preg and PE

Normal pregnancy is associated with vasodilation of the maternal uterine, renal and systemic vessels,[190] and reduction in the mechanisms of vascular contraction, likely due to increased plasma levels of estrogen and progesterone.[191,192] Estrogen causes relaxation of VSM of the rat aorta and uterine artery.[193,194] Also, progesterone inhibits contraction of rat blood vessels.[193] PE is associated with endothelial dysfunction, increased mechanisms of VSM contraction and inadequate remodeling of ECM.

Endothelial Dysfunction in PE

Normal and functional endothelium ensures healthy gestation and a favorable prognosis for the mother and fetus.[195] Brachial artery diameter and flow-mediated dilation increase as gestation progresses.[196] Also, endothelium-dependent bradykinin-induced relaxation is increased in small subcutaneous arteries from pregnant compared with non-pregnant women.[197] ATP also causes periodic bursts in cytosolic free Ca^{2+} concentration ($[Ca^{2+}]_c$) that are more frequent in uterine artery endothelial cells from pregnant compared with non-

pregnant ewes,[198] leading to increased vasodilation, decreased uterine artery myogenic tone, and adequate uterine blood flow during pregnancy.[199]

In addition to their effects on the uterus, gonadal hormones contribute to the vascular changes during pregnancy. Estrogen promotes endothelium-dependent vascular relaxation by increasing the release of NO, PGI$_2$ and EDHF.[200] Estrogen also causes relaxation of endothelium-denuded vessels by inhibiting the mechanisms of VSM contraction including $[Ca^{2+}]_c$ and protein kinase C.[201,202] Estrogen may have additional effects on the vascular cytoskeleton, ECM, lipid profile and inflammatory response.[200] Progesterone also causes vasodilation by mechanisms similar to estrogen.[202,203] Some of the vascular effect of estrogen could involve MMPs. In cultured human coronary artery and umbilical artery VSM cells, estrogen causes dose-dependent increases in MMP-2 levels in culture media.[49]

In contrast with normal pregnancy, women with PE show systemic endothelial cell dysfunction and HTN.[5] Brachial artery flow-mediated dilation is less in PE than normal pregnant women.[195,204] PE women also show less vasodilation in the radial artery when compared to normal pregnant women.[205] Bradykinin-induced relaxation is decreased in small subcutaneous arteries of PE compared with normal pregnant women.[197] Circulating endothelial cells and other markers of endothelial activation/injury such as soluble VCAM-1, E-selectin and endocan are increased in PE compared with normal pregnant women.[99,206–208] On the other hand, circulating endothelial progenitor cells are decreased and may serve as a marker of endothelial damage in PE women.[209]

The RUPP rat shows some of the characteristics of PE including high BP, proteinuria, decreased glomerular filtration rate and renal plasma flow, and IUGR, and therefore has been used to study the vascular mechanisms of HTN-Preg.[210–212] ACh is less potent in inducing relaxation in the aorta and mesenteric microvessels of RUPP than normal pregnant rats, suggesting endothelial damage in RUPP rats.[7,212] Endothelial cells release various vasodilator substances including nitric oxide (NO), prostacyclin (PGI$_2$) and endothelium-derived hyperpolarizing factor (EDHF) as well as contracting factors as endothelin-1 (ET-1) and thromboxane A2 (TXA$_2$). Endothelial dysfunction is associated with abnormal release of endothelium-derived vasodilator and vasoconstrictor factors.

Changes in Nitric Oxide (NO) in PE—NO is a potent vasodilator and relaxant of VSM. NO diffuses into VSM and increases cyclic guanosine monophosphate (cGMP), which promotes Ca^{2+} efflux, decreases VSM $[Ca^{2+}]_c$ and causes VSM relaxation. Nitrites are important metabolites of NO that are increased in serum of normal pregnant compared with non-pregnant women.[213] Plasma levels and urinary excretion of cGMP, a second messenger of NO, are also increased in normal pregnancy. NOS expression/activity increase in human uterine artery and in the placenta with gestational age.[214,215]. Also, urinary nitrite levels, mRNA expression of eNOS, iNOS and nNOS, and protein level of activated phospho-eNOS are increased in normal pregnant compared with virgin rats,[216] supporting pregnancy-related increase in NO.

Polymorphisms in *eNOS* gene could be a risk factor for PE. The VNTRa and 894T alleles of *eNOS* gene are associated with early and late severe PE, respectively. For the *eNOS*

VNTRb/a polymorphism, plasma NO metabolites are lower in subjects homozygous for the "a" allele. Also, the eNOS 894T allele is prone to selective proteolytic cleavage in endothelial cells and vascular tissues, thus accounting for the reduced NO production in subjects homozygous for this variant.[217] The T786C allele is also increased in PE compared with normal pregnant women.[218,219] Also, normal pregnant women with the TT phenotype for the T-786C allele have lower plasma nitrite levels than those with the CC phenotype,[220] and the TT phenotype has been proposed as a risk factor for PE in Tunisian women.[218]

Endothelial dysfunction is often associated with decreased NO due to decreased synthesis or bioavailability.[221] Clinical studies have shown increased[222] or decreased[223–225] plasma nitrite levels in PE compared with normal pregnant women. Also, urinary nitrite levels may not differ in PE versus normal pregnant women,[223] and this may not be solely related to dietary nitrate intake since a study that carefully controlled dietary nitrate/nitrite intake did not show decreased NO production in PE women.[226]

The lack of change in whole-body NO despite the increase in BP and the renal damage in PE suggest tissue-specific changes in NOS expression and NO bioavailability.[5] Studies have shown a decrease in nitrites in placentae from PE women.[225] Also, eNOS expression is decreased in umbilical cord of PE compared with normal pregnant women,[227] and the decrease is greater in women with severe PE.[228,229] However, some studies showed an increase in eNOS mRNA expression in placenta of PE women.[230] Also, while the levels of cGMP are increased during normal pregnancy, the plasma and urinary cGMP levels are not different in PE versus normal pregnant women.[223]

The role of NO has also been examined in animal models of HTN-Preg. In mid- to late pregnant rats, NOS blockade with N_ω-nitro-L-arginine methyl ester (L-NAME) causes PE-like manifestations including increased BP, renal vasoconstriction, proteinuria, thrombocytopenia and IUGR.[231] However, similar to the observation in humans, measurements of NO in HTN-Preg animals have not been consistent. Studies showed no difference in nitrite levels in L-NAME treated versus nontreated pregnant rats.[107] Also, while plasma nitrite levels were lower in RUPP than normal pregnant rats,[210] no differences were observed in urinary nitrite levels.[211,232] Also, consistent with the studies in human, no changes in circulating levels of the NOS substrate L-arginine were observed in RUPP versus normal pregnant rats.[233] Vascular function studies have shown increased aortic vascular reactivity to phenylephrine in L-NAME treated pregnant rats.[231] Also, ACh-induced relaxation, eNOS expression, and NO production are reduced in mesenteric artery and aorta of RUPP versus normal pregnant rats, supporting reduced NO synthesis in the vasculature.[7,212] In DOCA-salt rat model of HTN-Preg, NO-dependent relaxation was reduced in mesenteric vessels despite elevation of eNOS mRNA expression.[171]

We should note that NO has diverse functions that extend beyond vasodilation/VSM relaxation. NO plays a role in regulation of renal tubular function, immune modulation, and as an antioxidant, and dysregulation of these NO functions may be important mechanisms underlying HTN-Preg and PE.

Changes in Prostacyclin (PGI$_2$) in PE

PGI$_2$ is produced from the metabolism of arachidonic acid by cyclooxygenase 2 (COX)-2 and COX-1, and is a potent vasodilator and inhibitor of platelet aggregation. During normal pregnancy, the synthesis of 6-keto-PGF1α (a stable metabolite of PGI$_2$) is increased in fetoplacental tissues, suggesting a role in the regulation of the maternal and fetal circulation. [234,235] Plasma and urinary levels of PGF1α are decreased in severe PE, suggesting that the overall PGI$_2$ synthesis is diminished. Endothelial PGI$_2$ production may also decrease in PE. [236] While the release of PGI$_2$ may not be different in apical and basal trophoblasts of PE compared with normal pregnant women, the release of TXA$_2$, another COX product, from basal trophoblast cells is increased in PE and may contribute to increased placental vasoconstriction.[237]

Hydrogen Sulfide (H$_2$S)—In some arteries, relaxation responses cannot be fully explained by NO and PGI$_2$, and a possible role of H$_2$S has been suggested. Reduction in plasma levels of H$_2$S has been reported in PE pregnancies. Also, cystathionine-γ-lyase (CSE), the primary H$_2$S-synthesizing enzyme in the vasculature, is reduced in PE.[238]

Endothelium-Derived Hyperpolarizing Factor (EDHF) in PE—EDHF is a relaxing factor with specialized role in the control of small resistance vessels, local organ blood flow, peripheral vascular resistance and BP. Although the nature of EDHF is unclear, it often presents as K$^+$ efflux from endothelial cells through intermediate and small conductance Ca^{2+}-activated K$^+$ channels (IK$_{Ca}$ and SK$_{Ca}$, respectively) causing hyperpolarization of endothelial cells. Endothelial cell hyperpolarization then spreads via myoendothelial gap junctions (MEGJs) and connexins to cause VSM hyperpolarization, reduction of Ca^{2+} influx via voltage-dependent Ca^{2+} channels and suppression of the activity of phospolipase C, an enzyme involved in signal transduction in VSM. The opening of endothelial cell IK$_{Ca}$ and SK$_{Ca}$ could also cause some accumulation of K$^+$ ion in the myoendothelial interface which could induce VSM hyperpolarization by activating the inwardly rectifying K$^+$ (K$_{IR}$) channels and the Na$^+$/K$^+$-ATPase.[239] EDHF relaxation may also be caused by diffusible factors released from endothelial cells. EDHF may be a product of cytochrome P450 (CYP450), such as epoxyeicosatrienoic acid (EET), which activate large conductance K$_{Ca}$ (BK$_{Ca}$) and cause hyperpolarization of VSM. In some vessels, H$_2$O$_2$ may mimic EDHF-mediated responses by mechanisms involving K$_{Ca}$ activation.[240] Thus multiple EDHFs may exist and the identity of EDHF could vary depending on the vascular bed and animal species studied.[241]

In small subcutaneous and myometrial arteries of normal pregnant women, EDHF is responsible for ~50% of bradykinin-induced relaxation, acting together with NO to maintain proper vascular tonus.[242,243] The gap junction proteins connexins 37, 40 and 43 are partly involved in EDHF-mediated vascular response during normal pregnancy.[244] An increase in endothelial cell [Ca^{2+}]$_c$ activates IK$_{Ca}$ and SK$_{Ca}$ and EDHF-mediated dilation in uterine radial arteries of pregnant rats.[245] The delayed rectifier type of voltage-sensitive K$^+$ channels (K$_v$) may also play a role in EDHF-mediated dilation in uterine artery of pregnant rats.[246]

Studies in subcutaneous arteries from normal pregnant women have shown that MEGJs alone are the main pathway of EDHF-mediated relaxation, while in women with PE MEGJs alone or in combination with H_2O_2 or CYP450 epoxygenase metabolites of arachidonic acid could mediate EDHF-induced vasodilation. The changes in the role of MEGJs may be caused by morphological changes within the vascular wall during PE.[247] Small myometrial arteries from PE women also showed reduced vasodilatory responses that were attributed to decreased contribution of EDHF due to physical disruption of MEGJs.[248] Studies in mice have shown pregnancy-associated adaptations in the form of decreased sensitivity to phenylephrine and enhanced bradykinin-induced vasodilation in normal pregnant wild-type mice, but not in knockout mice lacking pregnane X receptor, a nuclear receptor that induces the expression of CYP450. Also, treatment with CYP450 inhibitor changed the vasodilatory response to bradykinin in wild-type but not the knockout mice, supporting that metabolites of CYP450 such as EET may play a role in the vascular adaptations during pregnancy.[249] As EET is one of the possible factors involved in EDHF-mediated relaxation, it is plausible to suggest that alterations in EDHF may lead to impaired vascular function and HTN-Preg. Although studies in mesenteric microvessels have suggested that the EDHF relaxation may not be compromised in RUPP versus normal pregnant rats,[212] decreased EDHF-mediated relaxation contributes to the vasoconstriction observed in HTN and diabetes, and its role in PE needs to be further examined.

Endothelin-1 (ET-1) in PE—ET-1 is a major endothelium-derived vasoconstrictor that could play a role in PE.[250] ET-1 synthesis is initiated from the long 203 amino acid preproET, which is cleaved by furin-like protease to biologically inactive 37 to 41 amino acid big-ET. Big-ET is cleaved by endothelin converting enzymes, members of the metalloprotease family, to produce active 21 amino acid ET-1. Circulating factors in PE such as cytokines, hypoxia and AT_1-AA may stimulate endothelial cells to produce ET-1.[250] In support, serum from PE women causes HUVECs to produce greater amounts of ET-1 than normal pregnant serum.[251] Some studies suggest that plasma ET-1 levels are elevated in PE. [252] ET-1 levels are higher during later stages of PE and return to normal levels within 48 hours after delivery,[253] suggesting that ET-1 may be involved in the progression rather than the initiation of PE. However, in most studies serum ET-1 levels do not differ in PE versus normal pregnant women, and higher levels of ET-1 are observed mainly in HELLP syndrome.[74,254,255] Of note, ET-1 is released in a paracrine fashion from endothelial cells directly toward VSMCs, and the increases in ET-1 levels in PE may be localized in tissues. Studies have shown a 4- to 8-fold increase in ET-1 levels in umbilical cord cells and in renal tissues during later stages of PE.[253,256] In perfused placentas under hypoxia, both the maternal and fetal side produce increased levels of ET-1.[257] In RUPP rats, preproET levels show a 45% increase in renal cortex and 22% increase in renal medulla.[258] Thus, circulating ET-1 levels may not always reflect local ET-1 levels in tissues. It is possible that in severe PE and in HELLP syndrome ET-1 production is so augmented such that it "loses" its paracrine directionality and leads to increased circulating ET-1 levels. In support, rat models that mimic severe PE and HELLP syndrome show increased plasma levels of ET-1.[124,259]

ET-1 may play a role in the pathogenesis of PE by inducing apoptosis of trophoblast cells and increasing oxidant and anti-angiogenic substances.[250,260] ET-1 activates endothelin

receptor type A (ET_AR) and type B (ET_BR).[261–263] ET-1 activation of VSM ET_AR stimulates Ca^{2+} release from the intracellular stores and Ca^{2+} entry through Ca^{2+} channels, and causes protein kinase C-dependent inhibition of K^+ channels leading to increased $[Ca^{2+}]_c$ and VSM contraction.[261] ET-1-induced vasoconstriction is reduced in mesenteric vessels of normal pregnant compared with non-pregnant rats,[264] and VSM ET_AR is reduced in aortic media and VSMCs of late-pregnant rat.[265] Also, treatment with ET_AR antagonist reduces BP in RUPP rat and other animal models of HTN-Preg.[258,266,267] Of note, among Brazilian women with PE, 52% of the patients with severe PE exhibited increases in ET_AR agonistic autoantibodies (ET_A-AA) which targets ET_AR and increases vasoconstriction.[268] ET-1 also activates ET_BR in endothelial cells and stimulates the release of NO, PGI_2, and EDHF which in turn reduce myogenic vascular tone, promote vasodilation of renal arteries and hyperfiltration in pregnant rats.[261,269] Downregulation of ET_BR may impair trophoblast invasion in PE and decrease microvascular dilation in pregnant rats. ET_BR expression is reduced in endothelial and renal cells of RUPP rats. Also, ET_BR-mediated NO production is less in the aorta and mesenteric artery of RUPP versus normal pregnant rats, supporting that downregulation of endothelial ET_BR could play a role in HTN-Preg.[212]

Thromboxane A_2 (TXA_2) in PE—TXA_2 is a potent stimulator of platelet aggregation, vasoconstriction, and VSM cell proliferation and mitogenesis. PE is associated with decreased vascular production of PGI_2 and increased production of TXA_2, and this may explain HTN and increased platelet aggregation in PE. Imbalance between urinary TXB_2 metabolites, markers of TXA_2 synthesis, and PGI_2 predates clinical symptoms of PE.[236] This led to the suggestion that antiplatelet agents such as low-dose aspirin and other thromboxane modulators might prevent or ameliorate PE. In clinical trials, women at high risk for PE showed no benefit of low dose aspirin as a preventive measure.[270] However, ozagrel, a thromboxane modulator, was found to reduce the occurrence of HTN-Preg and proteinuria,[271] making it important to further examine the role of TXA_2 in PE.

Vascular Smooth Muscle (VSM) Dysfunction in PE

VSM Ca^{2+} in PE—Ca^{2+} is a major determinant of VSM contraction and growth. Ca^{2+} release from the intracellular stores and Ca^{2+} entry from the extracellular space increase $[Ca^{2+}]_c$ in VSM. Ca^{2+} binds calmodulin to form Ca^{2+}-calmodulin complex which activates myosin light chain kinase, and causes myosin phosphorylation, actin-myosin interaction and VSM contraction. Decreased Ca^{2+} in VSM activates myosin phosphatase which dephosphorylates myosin light chain and leads to dissociation of the Ca^{2+}-calmodulin complex. Endothelium-derived relaxing factors act on VSM to decrease $[Ca^{2+}]_c$. During normal pregnancy, increased K_{Ca} channel activity decreases uterine artery tonicity and increases uteroplacental blood supply. In PE, K_{Ca} channel activity is suppressed leading to increased uterine artery $[Ca^{2+}]_c$, vasoconstriction and reduced fetal blood supply.[272] Myometrial vessels may show similar vasoconstriction responses to high KCl, phenylephrine and AngII in normal pregnancy and PE.[273] However, basal and agonist-stimulated $[Ca^{2+}]_c$ are reduced in renal arterial VSM of normal pregnant rats, and increased in pregnant rats treated with L-NAME.[274] AT_1R activation increases $[Ca^{2+}]_c$ in platelets, erythrocytes, and lymphocytes of PE women, and these effects subside 6 weeks after delivery.[182] AngII- and caffeine-induced contraction and $[Ca^{2+}]_c$ in Ca^{2+}-free solution are

similar in VSM of normal pregnant and RUPP rats, while KCl-induced maintained $[Ca^{2+}]_c$ in a Ca^{2+}-containing medium is greater in VSM of RUPP than normal pregnant rats, suggesting that it is not Ca^{2+} release from the intracellular stores, but Ca^{2+} entry from the extracellular space that increases vasoconstriction in HTN-Preg.[275]

Protein Kinase C (PKC) in PE—PKC is an important mediator of VSM contraction. PKC phosphorylates CPI-17 which inhibits myosin phosphatase and in turn increases myosin light chain phosphorylation and VSM contraction. PKC also phosphorylates calponin, an actin binding protein that inhibits myosin ATPase, leading to more actin-myosin interaction and VSM contraction. Phorbol esters activate PKC to cause VSM contraction with no detectable change in $[Ca^{2+}]_c$, suggesting that PKC increases Ca^{2+} sensitivity of the contractile proteins. PKC activity and contraction are reduced in uterine artery of late pregnant ewes and gilts and the aorta of late pregnant rats.[276–278] Also, the expression and subcellular redistribution of Ca^{2+}-dependent α-PKC and Ca^{2+}-independent δ- and ζ-PKC are reduced in aortic VSM of late pregnant rats, but are increased in L-NAME treated pregnant rat.[277,279] PKC may increase the production of AT_1-AA which stimulates AT_1R. In cultured rat cardiomyocytes treatment with IgG obtained from PE women enhances AT_1R-mediated response which is ameliorated with the PKC inhibitor calphostin C.[280] Increased BK_{Ca} channel activity inhibits PKC-mediated contraction in ovine uterine arteries during pregnancy, and gestational hypoxia may upregulate PKC and inhibit BK_{Ca}.[272] PKC inhibitors decrease TXA_2 mediated contraction in uterine and mesenteric arteries of virgin rats and in mesenteric artery of pregnant rats, supporting a role of PKC in mediating VSM contraction during pregnancy.[281] Blocking PKC can prevent PKC-mediated vasoconstriction in PE. Cicletanine is an anti-hypertensive drug that prevents the increase in PKC and lowers BP in HTN-Preg rats. MMP-2 may reduce vascular contraction by degrading the actin-binding protein and PKC substrate calponin,[282] and a decrease in MMP-2 would spare calponin and affect VSM contraction in HTN-Preg.

Mitogen-activated protein kinase (MAPK) is a serine/threonine protein kinase that regulates cellular activities such as gene expression, mitosis, differentiation, and VSM contraction. During VSM contraction, PKC may phosphorylate MAPK kinase which in turn phosphorylates and activates MAPK. Activated MAPK phosphorylates the actin-binding protein caldesmon thus preventing its inhibition of ATPase and increases actin-myosin interaction and VSM contraction. Changes in PKC activity in VSM during normal pregnancy and HTN-Preg could affect MAPK/caldesmon phosphorylation and VSM contraction.[283] In support, inhibition of p38 MAPK reduces TXA_2-induced contraction in uterine and mesenteric arteries of virgin and pregnant rats.[281]

VSM Rho-Kinase (ROCK) in PE—Rho is a family of small GTP-binding proteins that are involved in cell migration, cytoskeletal reorganization and VSM contraction. RhoA binding to GTP activates Rho-kinase (ROCK), and activated ROCK is inactivated by hydrolyzing GTP to GDP. ROCK has two isoforms, ROCK-1 (ROCK-I, ROKβ) and ROCK-2 (ROCK-II, ROKα), which contribute to the formation of microvilli structures during pregnancy. In PE, placental villi show abnormal expression of ROCK-II and apoptosis of the syncytium.[284] ROCK increases Ca^{2+} sensitivity of the contractile proteins in

subcutaneous resistance arteries of PE women.[285] Also, AngII via AT_1R induces RhoA/ROCK activity in L-NAME treated hypertensive rats.[286] ROCK may stimulate IL-17 to phosphorylate the inhibitory eNOS Thr495 residue thus decreasing NO production in PE.[287] ROCK Inhibition reduces TXA_2-induced contraction in uterine vessels of non-pregnant rats.[281] However, some studies show decreased ROCK mRNA expression in umbilical arteries of PE women,[270,288] making it important to further examine the role of ROCK in the vascular changes in PE.

Extracellular Matrix and Vascular Remodeling in PE

The extracellular matrix (ECM) is an integral component of the vascular wall. Pregnancy-associated changes in MMPs play a role in ECM and vascular remodeling, angiogenesis, and structural changes in blood vessels.[87] MMPs degrade different substrates including collagen, gelatin, and other proteins.[43,62] We have investigated the changes in MMPs substrates in the RUPP rat model of HTN-Preg. Picro-Sirius Red staining revealed an increase in collagen content in uterus, placenta and aorta of RUPP versus normal pregnant rats.[42] Because MMPs facilitate cell growth and migration by promoting proteolysis of ECM, the decreased MMP-2 and MMP-9 and increased collagen deposition in RUPP tissues could impede cell growth, proliferation and migration, and thus interfere with uteroplacental tissue invasion and uterine and placental growth. Also, while the aortic collagen content increased, there was a decrease in aortic tissue weight and thickness in RUPP rats, likely because the decreased MMPs and increased collagen content would interfere with VSMC growth and migration. The decreased MMP activity and increased vascular collagen content could also increase the blood vessel rigidity and decrease its plasticity and thus contribute to increased vascular resistance and HTN. This is consistent with reports that MMP-1, MMP-2, and MMP-9 activity is decreased and collagen deposition is increased in internal mammary artery from hypertensive compared with normotensive patients undergoing coronary artery bypass surgery.[289] It is important to note that collagen has 18 types and different subtypes.[290] MMP-2 can degrade collagen I, II, III, IV, V, VII, X, and XI while MMP-9 can degrade collagen IV, V, VII, X, XIV.[43,62,291] Studies should measure the changes in various collagen subtypes in HTN-Preg. Also, RT-PCR experiments should determine whether any increases in a collagen subtype are due to decreased degradation or increased *de novo* collagen mRNA expression and protein biosynthesis.

While MMPs are largely known for their proteolytic effects on ECM, we and others have identified novel MMP-induced downstream pathways that could affect membrane receptors, cell signaling and vascular function.[59,292–294] Prolonged increases in intravascular pressure and wall tension cause increases in MMP-2 and MMP-9 expression.[293–295] Also, MMP-2 and MMP-9 cause relaxation of phenylephrine precontracted rat aorta[294] and inferior vena cava.[293,295] Thus during normal pregnancy, plasma volume expansion could lead to increased MMP-2 and MMP-9, vasodilation and decreased BP. The decrease in vascular MMP-2 and MMP-9 is expected to hinder vasorelaxation in RUPP rats, consistent with the observed decrease in ACh-induced relaxation in blood vessels of RUPP versus pregnant rats.[7,264]

MMPs break down big-ET-1 into different endothelins with different affinities for ET_AR and ET_BR. MMPs degrade big-ET into ET-1, which largely stimulates ET_AR and promotes vasoconstriction.[296] Studies have suggested a role of ET-1 and ET_AR in some forms of HTN including HTN-Preg.[258,266,297–299] In omental vessels of pregnant women, MMP-1 causes vasoconstriction and enhances reactivity to AngII via an endothelium-dependent protease-activated receptor (PAR) and ET-1 pathway.[59] ET-1 in turn can stimulate VSM contraction mechanisms including $[Ca^{2+}]_c$, PKC, and ROCK.[300–302]

MMP-2 and MMP-9 could degrade big-ET to ET_{1-32} which preferentially stimulates endothelial ET_BR and promotes relaxation. MMP-2 and MMP-9 cause vascular relaxation by decreasing Ca^{2+} influx into VSM,[294] and a decrease in these MMPs could lead to increased Ca^{2+} influx, vasoconstriction and HTN-Preg. We have shown increases in MMP-2, MMP-9 and ET_BR in normal pregnant rats.[50,264,292] ET_BR is downregulated in RUPP rats, and infusion of the ET_BR antagonist BQ788 increases BP in pregnant rats.[212] Also, MMP-2 induces vascular relaxation partly via hyperpolarization and activation of K^+ channels.[293,295] Thus, the decrease in MMP-2 and MMP-9 mediated relaxation may contribute to the enhanced vascular contraction and increased BP in RUPP rat model of HTN-preg.[7,106,212]

Prediction and Management of PE

PE has a relatively long preclinical phase before manifesting in late gestation, and the identification of women at risk, early diagnosis using biomarkers, and prompt management could improve the maternal and perinatal outcome.[5] Thrombocytopenia is common and progresses with severity of PE.[303] Longitudinal studies have shown that women who develop PE have higher mean platelet volume 4.6 weeks prior to the appearance of symptoms.[270] Doppler screening at 23 weeks of pregnancy and detection of early diastolic bilateral uterine artery notching in the waveform could predict PE. PE women with uterine artery notching have altered levels of fibrinolytic activators and inhibitors such as tissue-type plasminogen activator (t-PA), PAI-1, PAI-2, plasmin-α2-antiplasmin (PAP) and D-dimers. Increased t-PA levels in PE women appears to be related to endothelial cell activation/dysfunction.[304] Also, a decrease in brachial artery flow-mediated vasodilation is an early indicator of endothelial dysfunction between the 24th and 28th gestational weeks and before clinical diagnosis of PE. The sensitivity of flow-mediated vasodilation is 87.5% and 95.5% for the prediction of early and late PE, respectively.[195]

Biomarkers allow early assessment in asymptomatic pregnant women at increased risk of PE based on their clinical history of PE or HTN in a previous pregnancy, or pre-pregnancy state e.g. HTN, obesity, or autoimmune disease. Angiogenic imbalance is an important feature in PE. Measurements of plasma VEGF, PlGF, sFlt-1 and sEng may help early detection in asymptomatic women at high risk for PE.[5] In PE, circulating levels of sFlt-1 are increased more than one month before the onset of clinical symptoms, and PlGF is decreased in women who subsequently develop PE from the end of the first trimester.[305] The sFlt-1/PlGF ratio is increased in both early and late PE.[92] A meta-analysis of 20 different studies suggest that the overall diagnostic accuracy of sFlt-1/PlGF ratio for PE is relatively high, and is higher in early than late PE.[306] However, patients with late onset PE could show lower levels of sFlt1/PlGF ratio compared to early onset PE,[92] suggesting that other factors may be

involved and could serve as markers of PE. sFlt1–14 is human-specific splicing variant of VEGFR-1 produced by nonendothelial cells and a potent inhibitor of VEGF. The expression of sFlt1–14 is elevated in placenta of PE women, specifically in abnormal clusters of degenerative syncytiotrophoblasts known as syncytial knots.[307]

Abnormal maternal immunological response could help in predicting PE in early pregnancy, and is often presented as a change in monocytes and natural killer (NK) cells, increased pro-inflammatory cytokines, increased AT_1-AA, and activation of AT_1R.[5,308] The alternate complement pathway is upregulated in PE and plasma levels of factor B-derived Bb fragment are higher in PE than normal pregnant women.[270] TNFα levels could be an early predictor of PE. Plasma obtained at gestational weeks 11–13 showed high TNFα levels in women who later developed PE.[309] Elevated plasma TNFα levels in association with changes in uterine artery Doppler at 11–13th gestational weeks have a 100% sensitivity in predicting PE.[310] Also, plasma levels of sTNF-R1 and sTNF-R2 are elevated in PE.[311] Other reports suggest that plasma TNFα levels may be useful in predicting PE in the early third trimester, but not the first or second trimesters.[312]

Uric acid is a marker of oxidative stress, tissue injury and renal dysfunction. During normal pregnancy, uric acid levels decrease initially, but then gradually increase over gestational time. Hypoxia and ischemia of the placenta and cytokines such as interferon induce expression of xanthine oxidase which increases the production of uric acid and ROS. During PE, hyperuricemia may develop as early as 10th week of gestation. Increased circulating uric acid may attenuate trophoblast invasion and spiral artery remodeling, stimulate monocytes to produce TNFα, IL-6 and IL-1β, and contribute to endothelial dysfunction and reduced NO production.[313] Plasma levels of malondialdehyde, a highly reactive compound and a marker for oxidative stress are also higher in PE than normal pregnant women, and positively associated with maternal plasma sFlt-1 levels.[314]

Elevated serum level of placental glycoprotein pregnancy-associated plasma protein-A (PAPP-A) and of placental protein 13 (PP13), together with abnormal Doppler ultrasound of the uterine artery, have a high predictive value in PE.[315] Also, serum levels of fetal hemoglobin, α1-microglobulin, activin A, and inhibin A are altered in PE.[314,316]

Amniocentesis and amniotic fluid analysis in the second trimester may be useful in predicting PE. Insulin-like factor 3 (INSL3) is a member of the insulin/relaxin family of peptide hormones made by the fetal testis and is responsible for the first trans-abdominal phase of testicular descent. In the presence of a male fetus, INSL3 is elevated in amniotic fluid samples of women who subsequently develop PE.[270] The amniotic fluid levels of inhibin A, a glycoprotein produced by syncytiotrophoblast, are higher in pregnant women who subsequently develop severe PE than in normal pregnant women[317]. Also, the level of sFlt-1 is higher in the amniotic fluid of PE than normal pregnant women.[318]

Microarray analysis could be used to screen the placental transcriptome for upregulated and downregulated genes in PE. The mRNA levels of plasminogen activator inhibitor-1 (PAI-1), tissue-type plasminogen activator (t-PA), VEGFR-1 (Flt-1), endoglin, placenta-specific protein 1 and P-selectin were increased in plasma from pregnant women who later

developed PE. Flt-1 had the highest detection rate while placenta-specific protein 1 had the lowest detection rate, with the best multivariable model obtained by the combination of all markers.[319] miRNA-206 interacts with several genes involved in PE and is elevated at gestational week 28 in plasma and placenta from women who subsequently develop PE,[320] although other studies show little predictive value of miRNAs.[321]

Measurements of MMPs have not been consistent in PE, with some studies showing an increase in MMP-2 and MMP-9,[55] while other studies showing a decrease in MMP-9.[41] However, plasma MMPs represents global changes in MMPs in different tissues, and localized changes in uteroplacental tissues and fluids may carry more predictive value.

In search for other PE biomarkers, studies have shown that pregnant mice deficient in catechol-O-methyltransferase (COMT) show a PE-like phenotype. COMT deficiency leads to an absence or decrease of 2-methoxyestradiol (2-ME), a natural metabolite of estradiol, which is normally elevated during the third trimester of normal pregnancy. Administration of 2-ME ameliorated several of the PE-like features in the $Comt^{-/-}$ pregnant mice, and suppressed placental hypoxia, HIF-1α expression, and sFlt-1 elevation. Plasma levels of COMT and 2-ME are decreased in PE women, and may be used as biomarkers for PE.[322] Despite the existence of several markers for PE, their predictive value needs to be further assessed in order to identify the best marker combinations for use in clinical settings.

Currently, inducing labor and delivery of the fetus and placenta are the most effective measures for PE. Prenatal care is most important in management of PE and includes bed rest and anti-HTN drugs such as oral nifedipine or intravenous hydralazine or diazoxide, depending on severity of HTN. International guidelines recommend one antihypertensive agent e.g. methyldopa, labetalol, another beta-blocker (acebutolol, metoprolol, pindolol, propranolol), or Ca^{2+} channel blocker (nifedipine).[323] Angiotensin receptor blockers (ARBs) and angiotensin converting enzyme (ACE) inhibitors should not be used due to their teratogenic effects, and atenolol and prazosin are not recommended prior to delivery. If PE worsens to eclampsia, airway patency should be maintained to prevent fluid aspiration, and anticonvulsants are given, with Mg^{2+} sulfate infusion being the drug of choice.[324]

Sildenafil may be useful in women with severe early-onset IUGR, as it could promote fetal growth with no maternal side effects.[325] Sildenafil citrate dilates myometrial artery and restores endothelial cell integrity in placental vessels of L-NAME treated mouse model of HTN-Preg.[326] Eculizumab, an anti-C5 antibody, normalized laboratory values and prolonged pregnancy by 17 days in a woman with PE/HELLP syndrome, suggesting the benefits of manipulating the complement system during PE. However, complement inhibitors could increase susceptibility to infection and their long-term use requires close monitoring.[327]

Correcting the angiogenic imbalance may be beneficial in PE. In trophoblast cells and HUVECs treated with cobalt chloride to simulate hypoxic conditions, the free radical scavenger edaravone inhibits sFlt-1 expression in trophoblast cells and protects against the decrease in vascular development and tube formation in HUVECs.[328] VEGF could improve the angiogenic imbalance, but may impair bradykinin-induced vascular relaxation and enhance basal tone and vascular permeability in PE.[13] Modulators of PlGF could be more

promising in PE, and low molecular weight heparin increases circulating PlGF levels during the third trimester.[329] Infusion of PlGF or VEGF reduces BP in RUPP rats.[117,330]

TNFα antagonists such as etanercept decrease BP, increase eNOS expression and decrease ET-1 levels in RUPP rats.[126,331] IL-17 soluble receptor C inhibits IL-17, prevents the recruitment of host defense cells, suppresses the inflammatory response, decreases AT$_1$-AA and ROS, and ameliorates HTN and pup and placental weight in RUPP rats.[332] Infusion of anti-inflammatory IL-10 decreases BP in DOCA/salt rat model of HTN-Preg.[333]

Another approach is to aim at downstream targets affected by cytoactive factors. If MMPs are a central target in HTN-Preg, then modulating MMP expression/activity should promote vasodilation and reduce BP. Doxycycline is an MMP inhibitor that could alleviate HTN and vascular dysfunction, but may decrease placenta weight and cause IUGR in normal pregnant rats, and reduce trophoblast invasion and placental perfusion in HTN-Preg rats.[135] Novel approaches to indirectly or directly correct mediators of microvascular dysfunction should provide new strategies in the management of HTN-Preg and PE.

Perspective

Normal pregnancy is associated with uteroplacental and vascular remodeling in order to adapt for the growing fetus. Genetic and environmental factors cause defective placentation, altered maternal immune response, and abnormal expression of integrins, inflammatory cytokines and MMPs, leading to apoptosis of trophoblast cells, shallow trophoblastic invasion and inadequate spiral artery remodeling, RUPP, and placental ischemia/hypoxia. Ischemic/hypoxic placenta causes the release of bioactive factors such as sFlt-1, sEng, TNFα, IL-6, HIF, ROS and AT$_1$-AA. Bioactive factors could affect endothelial cells, cause endothelial dysfunction, decrease vasodilators or increase ET-1, or target MMPs in ECM leading to increased vasoconstriction, altered uteroplacental and vascular remodeling, increased uteroplacental and vascular collagen, growth-restrictive remodeling, and HTN-Preg.[156,334] These bioactive factors and vascular mediators may be different with respect to timing, severity and mechanisms in early versus late-onset PE. Further understanding of the interaction between bioactive factors, vascular mediators and molecular mechanisms should help design more efficient measures for early detection and management of PE.

ACKNOWLEDGEMENTS

List Of Abbreviations:

2-ME	2-methoxy estradiol
ACh	acetylcholine

AngII	angiotensin II
ARB	angiotensin receptor blocker
AT$_1$R	AngII type 1 receptor
AT$_1$-AA	AngII AT$_1$R agonistic autoantibodies
BP	blood pressure
$[Ca^{2+}]_c$	cytosolic free Ca^{2+} concentration
cGMP	cyclic guanosine monophosphate
COX	cyclooxygenase
DOCA	deoxycorticosterone acetate
ECM	extracellular matrix
EDHF	endothelium-derived hyperpolarizing factor
eNOS	endothelial nitric oxide synthase
EMMPRIN	extracellular MMP inducer
EGF	epidermal growth factor
ET-1	endothelin-1
HO	hemeoxygenase
H$_2$O$_2$	hydrogen peroxide
HIF	hypoxia-inducible factor
HELLP	hemolysis elevated liver enzymes low platelets
HTN-Preg	hypertension in pregnancy
HUVECs	human umbilical vein endothelial cells
ICAM-1	intercellular adhesion molecule-1
IL	interleukin
IUGR	intrauterine growth restriction
L-NAME	N$_\omega$-nitro-L-arginine methyl ester
MAPK	mitogen-activated protein kinase
MEGJ	myoendothelial gap junction
MMP	matrix metalloproteinase
NO	nitric oxide

NOS	nitric oxide synthase
O2•-	superoxide anion
PE	preeclampsia
PGI$_2$	prostacyclin
PlGF	placental growth factor
PKC	protein kinase C
RAS	renin-angiotensin-system
ROCK	Rho-kinase
ROS	reactive oxygen species
RUPP	reduced uterine perfusion pressure
sEng	soluble endoglin
sFlt-1	soluble fms-like tyrosine kinase-1
TGF-β	transforming growth factor-β
TIMP	tissue inhibitor of metalloproteinases
TNFα	tumor necrosis factor-α
TXA$_2$	thromboxane A2
VEGF	vascular endothelial growth factor
VCAM-1	vascular cell adhesion molecule-1
VSM	vascular smooth muscle

REFERENCES

1. Ouzounian JG, Elkayam U. Physiologic changes during normal pregnancy and delivery. Cardiol Clin. 2012;30(3):317–329. [PubMed: 22813360]

2. Poston L, McCarthy AL, Ritter JM. Control of vascular resistance in the maternal and feto-placental arterial beds. Pharmacology & therapeutics. 1995;65(2):215–239. [PubMed: 7792316]

3. Thornburg KL, Jacobson SL, Giraud GD, Morton MJ. Hemodynamic changes in pregnancy. Seminars in perinatology. 2000;24(1):11–14. [PubMed: 10709851]

4. Valdes G, Kaufmann P, Corthorn J, Erices R, Brosnihan KB, Joyner-Grantham J. Vasodilator factors in the systemic and local adaptations to pregnancy. Reproductive biology and endocrinology : RB&E. 2009;7:79. [PubMed: 19646248]

5. Ali SM, Khalil RA. Genetic, immune and vasoactive factors in the vascular dysfunction associated with hypertension in pregnancy. Expert opinion on therapeutic targets. 2015;19(11):1495–1515. [PubMed: 26294111]

6. Say L, Chou D, Gemmill A, Tuncalp O, Moller AB, Daniels J, Gulmezoglu AM, Temmerman M, Alkema L. Global causes of maternal death: a WHO systematic analysis. The Lancet. Global health. 2014;2(6):e323–333. [PubMed: 25103301]

7. Crews JK, Herrington JN, Granger JP, Khalil RA. Decreased endothelium-dependent vascular relaxation during reduction of uterine perfusion pressure in pregnant rat. Hypertension. 2000;35(1 Pt 2):367–372. [PubMed: 10642326]

8. Gilbert JS, Babcock SA, Granger JP. Hypertension produced by reduced uterine perfusion in pregnant rats is associated with increased soluble fms-like tyrosine kinase-1 expression. Hypertension. 2007;50(6):1142–1147. [PubMed: 17923588]

9. Alexander BT, Cockrell K, Cline FD, Llinas MT, Sedeek M, Granger JP. Effect of angiotensin II synthesis blockade on the hypertensive response to chronic reductions in uterine perfusion pressure in pregnant rats. Hypertension. 2001;38(3 Pt 2):742–745. [PubMed: 11566968]

10. Granger JP, Alexander BT, Llinas MT, Bennett WA, Khalil RA. Pathophysiology of preeclampsia: linking placental ischemia/hypoxia with microvascular dysfunction. Microcirculation. 2002;9(3): 147–160. [PubMed: 12080413]

11. Shah DA, Khalil RA. Bioactive factors in uteroplacental and systemic circulation link placental ischemia to generalized vascular dysfunction in hypertensive pregnancy and preeclampsia. Biochemical pharmacology. 2015;95(4):211–226. [PubMed: 25916268]

12. Pereira RD, De Long NE, Wang RC, Yazdi FT, Holloway AC, Raha S. Angiogenesis in the placenta: the role of reactive oxygen species signaling. BioMed research international. 2015;2015:814543. [PubMed: 25705690]

13. VanWijk MJ, Kublickiene K, Boer K, VanBavel E. Vascular function in preeclampsia. Cardiovascular research. 2000;47(1):38–48. [PubMed: 10869528]

14. Khalil RA, Granger JP. Vascular mechanisms of increased arterial pressure in preeclampsia: lessons from animal models. American journal of physiology. Regulatory, integrative and comparative physiology. 2002;283(1):R29–45.

15. Founds SA, Conley YP, Lyons-Weiler JF, Jeyabalan A, Hogge WA, Conrad KP. Altered global gene expression in first trimester placentas of women destined to develop preeclampsia. Placenta. 2009;30(1):15–24. [PubMed: 19027158]

16. van Dijk M, Oudejans CB. STOX1: Key player in trophoblast dysfunction underlying early onset preeclampsia with growth retardation. Journal of pregnancy. 2011;2011:521826. [PubMed: 21490791]

17. Doridot L, Passet B, Mehats C, Rigourd V, Barbaux S, Ducat A, Mondon F, Vilotte M, Castille J, Breuiller-Fouche M, Daniel N, le Provost F, Bauchet AL, Baudrie V, Hertig A, Buffat C, Simeoni U, Germain G, Vilotte JL, Vaiman D. Preeclampsia-like symptoms induced in mice by fetoplacental expression of STOX1 are reversed by aspirin treatment. Hypertension. 2013;61(3): 662–668. [PubMed: 23357179]

18. Sasaki Y, Darmochwal-Kolarz D, Suzuki D, Sakai M, Ito M, Shima T, Shiozaki A, Rolinski J, Saito S. Proportion of peripheral blood and decidual CD4(+) CD25(bright) regulatory T cells in pre-eclampsia. Clinical and experimental immunology. 2007;149(1):139–145. [PubMed: 17459078]

19. Rahimzadeh M, Norouzian M, Arabpour F, Naderi N. Regulatory T-cells and preeclampsia: an overview of literature. Expert Rev Clin Immunol. 2016;12(2):209–227. [PubMed: 26580672]

20. Tanbe AF, Khalil RA. Circulating and Vascular Bioactive Factors during Hypertension in Pregnancy. Current bioactive compounds. 2010;6(1):60–75. [PubMed: 20419111]

21. Rosenberg TJ, Garbers S, Lipkind H, Chiasson MA. Maternal obesity and diabetes as risk factors for adverse pregnancy outcomes: differences among 4 racial/ethnic groups. Am J Public Health. 2005;95(9):1545–1551. [PubMed: 16118366]

22. Lamminpaa R, Vehvilainen-Julkunen K, Gissler M, Heinonen S. Preeclampsia complicated by advanced maternal age: a registry-based study on primiparous women in Finland 1997–2008. BMC Pregnancy Childbirth. 2012;12:47. [PubMed: 22687260]

23. Kanagal DV, Rajesh A, Rao K, Devi UH, Shetty H, Kumari S, Shetty PK. Levels of Serum Calcium and Magnesium in Pre-eclamptic and Normal Pregnancy: A Study from Coastal India. J Clin Diagn Res. 2014;8(7):OC01–04.

24. Spradley FT, Palei AC, Granger JP. Increased risk for the development of preeclampsia in obese pregnancies: weighing in on the mechanisms. American journal of physiology. Regulatory, integrative and comparative physiology. 2015;309(11):R1326–1343.

25. Zarate A, Saucedo R, Valencia J, Manuel L, Hernandez M. Early disturbed placental ischemia and hypoxia creates immune alteration and vascular disorder causing preeclampsia. Archives of medical research. 2014;45(7):519–524. [PubMed: 25450587]

26. Hall D, Gebhardt S, Theron G, Grove D. Pre-eclampsia and gestational hypertension are less common in HIV infected women. Pregnancy hypertension. 2014;4(1):91–96. [PubMed: 26104261]

27. Trowsdale J, Moffett A. NK receptor interactions with MHC class I molecules in pregnancy. Semin Immunol. 2008;20(6):317–320. [PubMed: 18656382]

28. Hiby SE, Walker JJ, O'Shaughnessy KM, Redman CW, Carrington M, Trowsdale J, Moffett A. Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success. J Exp Med. 2004;200(8):957–965. [PubMed: 15477349]

29. Lillegard KE, Johnson AC, Lojovich SJ, Bauer AJ, Marsh HC, Gilbert JS, Regal JF. Complement activation is critical for placental ischemia-induced hypertension in the rat. Mol Immunol. 2013;56(1–2):91–97. [PubMed: 23685261]

30. Leik CE, Walsh SW. Neutrophils infiltrate resistance-sized vessels of subcutaneous fat in women with preeclampsia. Hypertension. 2004;44(1):72–77. [PubMed: 15148293]

31. Regal JF, Lillegard KE, Bauer AJ, Elmquist BJ, Loeks-Johnson AC, Gilbert JS. Neutrophil Depletion Attenuates Placental Ischemia-Induced Hypertension in the Rat. PloS one. 2015;10(7):e0132063. [PubMed: 26135305]

32. McMaster MT, Zhou Y, Fisher SJ. Abnormal placentation and the syndrome of preeclampsia. Seminars in nephrology. 2004;24(6):540–547. [PubMed: 15529288]

33. Iwaki T, Yamamoto K, Matsuura T, Sugimura M, Kobayashi T, Kanayama N. Alteration of integrins under hypoxic stress in early placenta and choriocarcinoma cell line BeWo. Gynecol Obstet Invest. 2004;57(4):196–203. [PubMed: 14963368]

34. Roberts JM, Escudero C. The placenta in preeclampsia. Pregnancy hypertension. 2012;2(2):72–83. [PubMed: 22745921]

35. Baig S, Kothandaraman N, Manikandan J, Rong L, Ee KH, Hill J, Lai CW, Tan WY, Yeoh F, Kale A, Su LL, Biswas A, Vasoo S, Choolani M. Proteomic analysis of human placental syncytiotrophoblast microvesicles in preeclampsia. Clin Proteomics. 2014;11(1):40. [PubMed: 25469110]

36. Perez-Sepulveda A, Torres MJ, Khoury M, Illanes SE. Innate immune system and preeclampsia. Front Immunol. 2014;5:244. [PubMed: 24904591]

37. Fei X, Hongxiang Z, Qi C, Daozhen C. Maternal plasma levels of endothelial dysfunction mediators including AM, CGRP, sICAM-1 and tHcy in pre-eclampsia. Adv Clin Exp Med. 2012;21(5):573–579. [PubMed: 23356193]

38. Kim SY, Ryu HM, Yang JH, Kim MY, Ahn HK, Lim HJ, Shin JS, Woo HJ, Park SY, Kim YM, Kim JW, Cho EH. Maternal serum levels of VCAM-1, ICAM-1 and E-selectin in preeclampsia. J Korean Med Sci. 2004;19(5):688–692. [PubMed: 15483345]

39. Li Q, Pan Z, Wang X, Gao Z, Ren C, Yang W. miR-125b-1–3p inhibits trophoblast cell invasion by targeting sphingosine-1-phosphate receptor 1 in preeclampsia. Biochemical and biophysical research communications. 2014;453(1):57–63. [PubMed: 25251470]

40. Anton L, Olarerin-George AO, Hogenesch JB, Elovitz MA. Placental expression of miR-517a/b and miR-517c contributes to trophoblast dysfunction and preeclampsia. PloS one. 2015;10(3):e0122707. [PubMed: 25799546]

41. Montagnana M, Lippi G, Albiero A, Scevarolli S, Salvagno GL, Franchi M, Guidi GC. Evaluation of metalloproteinases 2 and 9 and their inhibitors in physiologic and pre-eclamptic pregnancy. J Clin Lab Anal. 2009;23(2):88–92. [PubMed: 19288452]

42. Li W, Mata KM, Mazzuca MQ, Khalil RA. Altered matrix metalloproteinase-2 and −9 expression/activity links placental ischemia and anti-angiogenic sFlt-1 to uteroplacental and vascular remodeling and collagen deposition in hypertensive pregnancy. Biochemical pharmacology. 2014;89(3):370–385. [PubMed: 24704473]

43. Raffetto JD, Khalil RA. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol. 2008;75(2):346–359. [PubMed: 17678629]

44. Ulbrich SE, Meyer SU, Zitta K, Hiendleder S, Sinowatz F, Bauersachs S, Buttner M, Frohlich T, Arnold GJ, Reichenbach HD, Wolf E, Meyer HH. Bovine endometrial metallopeptidases MMP14

and MMP2 and the metallopeptidase inhibitor TIMP2 participate in maternal preparation of pregnancy. Mol Cell Endocrinol. 2011;332(1–2):48–57. [PubMed: 20887771]

45. Mishra B, Kizaki K, Koshi K, Ushizawa K, Takahashi T, Hosoe M, Sato T, Ito A, Hashizume K. Expression of extracellular matrix metalloproteinase inducer (EMMPRIN) and its related extracellular matrix degrading enzymes in the endometrium during estrous cycle and early gestation in cattle. Reprod Biol Endocrinol. 2010;8:60. [PubMed: 20540754]

46. Shimonovitz S, Hurwitz A, Dushnik M, Anteby E, Geva-Eldar T, Yagel S. Developmental regulation of the expression of 72 and 92 kd type IV collagenases in human trophoblasts: a possible mechanism for control of trophoblast invasion. American journal of obstetrics and gynecology. 1994;171(3):832–838. [PubMed: 7522400]

47. Isaka K, Usuda S, Ito H, Sagawa Y, Nakamura H, Nishi H, Suzuki Y, Li YF, Takayama M. Expression and activity of matrix metalloproteinase 2 and 9 in human trophoblasts. Placenta. 2003;24(1):53–64. [PubMed: 12495660]

48. Qiu Q, Yang M, Tsang BK, Gruslin A. EGF-induced trophoblast secretion of MMP-9 and TIMP-1 involves activation of both PI3K and MAPK signalling pathways. Reproduction. 2004;128(3):355–363. [PubMed: 15333786]

49. Wingrove CS, Garr E, Godsland IF, Stevenson JC. 17beta-oestradiol enhances release of matrix metalloproteinase-2 from human vascular smooth muscle cells. Biochim Biophys Acta. 1998;1406(2):169–174. [PubMed: 9573355]

50. Dang Y, Li W, Tran V, Khalil RA. EMMPRIN-mediated induction of uterine and vascular matrix metalloproteinases during pregnancy and in response to estrogen and progesterone. Biochemical pharmacology. 2013;86(6):734–747. [PubMed: 23856290]

51. Yu Y, Wang L, Liu T, Guan H. MicroRNA-204 suppresses trophoblast-like cell invasion by targeting matrix metalloproteinase-9. Biochemical and biophysical research communications. 2015;463(3):285–291. [PubMed: 26003727]

52. Plaks V, Rinkenberger J, Dai J, Flannery M, Sund M, Kanasaki K, Ni W, Kalluri R, Werb Z. Matrix metalloproteinase-9 deficiency phenocopies features of preeclampsia and intrauterine growth restriction. Proc Natl Acad Sci U S A. 2013;110(27):11109–11114. [PubMed: 23776237]

53. Omran OM, Shokry M, Ismail H, Omar G, Rezk M. Expression of matrix metalloproteinases 2 and 9 in human trophoblasts of normal and preeclamptic placentas. Int J Health Sci (Qassim). 2011;5(2 Suppl 1):21–23. [PubMed: 23284563]

54. Choi SY, Yun J, Lee OJ, Han HS, Yeo MK, Lee MA, Suh KS. MicroRNA expression profiles in placenta with severe preeclampsia using a PNA-based microarray. Placenta. 2013;34(9):799–804. [PubMed: 23830491]

55. Eleuterio NM, Palei AC, Rangel Machado JS, Tanus-Santos JE, Cavalli RC, Sandrim VC. Positive correlations between circulating adiponectin and MMP2 in preeclampsia pregnant. Pregnancy hypertension. 2015;5(2):205–208. [PubMed: 25943646]

56. Seo KW, Lee SJ, Kim YH, Bae JU, Park SY, Bae SS, Kim CD. Mechanical stretch increases MMP-2 production in vascular smooth muscle cells via activation of PDGFR-beta/Akt signaling pathway. PLoS One. 2013;8(8):e70437. [PubMed: 23950935]

57. Li HX, Kong FJ, Bai SZ, He W, Xing WJ, Xi YH, Li GW, Guo J, Li HZ, Wu LY, Wang R, Yang GD, Tian Y, Xu CQ. Involvement of calcium-sensing receptor in oxLDL-induced MMP-2 production in vascular smooth muscle cells via PI3K/Akt pathway. Mol Cell Biochem. 2012;362(1–2):115–122. [PubMed: 22083546]

58. Deng CL, Ling ST, Liu XQ, Zhao YJ, Lv YF. Decreased expression of matrix metalloproteinase-1 in the maternal umbilical serum, trophoblasts and decidua leads to preeclampsia. Exp Ther Med. 2015;9(3):992–998. [PubMed: 25667666]

59. Nugent WH, Mishra N, Strauss JF 3rd, Walsh SW. Matrix Metalloproteinase 1 Causes Vasoconstriction and Enhances Vessel Reactivity to Angiotensin II via Protease-Activated Receptor 1. Reproductive sciences. 2016;23(4):542–548. [PubMed: 26438597]

60. Roy SC, Ghosh J. Dynamic in vivo changes in the activities of gelatinases, matrix metalloproteinases (MMPs), and tissue inhibitor of metalloproteinases (TIMPs) in buffalo (Bubalus bubalis) uterine luminal fluid during estrous cycle and early pregnancy. Mol Reprod Dev. 2010;77(11):944–953. [PubMed: 20886603]

61. Harris LK, Smith SD, Keogh RJ, Jones RL, Baker PN, Knofler M, Cartwright JE, Whitley GS, Aplin JD. Trophoblast- and vascular smooth muscle cell-derived MMP-12 mediates elastolysis during uterine spiral artery remodeling. Am J Pathol. 2010;177(4):2103–2115. [PubMed: 20802175]

62. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 2003;92(8):827–839. [PubMed: 12730128]

63. Biswas C, Zhang Y, DeCastro R, Guo H, Nakamura T, Kataoka H, Nabeshima K. The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res. 1995;55(2):434–439. [PubMed: 7812975]

64. Huet E, Gabison EE, Mourah S, Menashi S. Role of emmprin/CD147 in tissue remodeling. Connect Tissue Res. 2008;49(3):175–179. [PubMed: 18661337]

65. Orshal JM, Khalil RA. Reduced endothelial NO-cGMP-mediated vascular relaxation and hypertension in IL-6-infused pregnant rats. Hypertension. 2004;43(2):434–444. [PubMed: 14707155]

66. LaMarca BB, Bennett WA, Alexander BT, Cockrell K, Granger JP. Hypertension produced by reductions in uterine perfusion in the pregnant rat: role of tumor necrosis factor-alpha. Hypertension. 2005;46(4):1022–1025. [PubMed: 16144982]

67. Gilbert JS, Gilbert SA, Arany M, Granger JP. Hypertension produced by placental ischemia in pregnant rats is associated with increased soluble endoglin expression. Hypertension. 2009;53(2): 399–403. [PubMed: 19075097]

68. Powe CE, Levine RJ, Karumanchi SA. Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation. 2011;123(24):2856–2869. [PubMed: 21690502]

69. Jardim LL, Rios DR, Perucci LO, de Sousa LP, Gomes KB, Dusse LM. Is the imbalance between pro-angiogenic and anti-angiogenic factors associated with preeclampsia? Clinica chimica acta; international journal of clinical chemistry. 2015;447:34–38. [PubMed: 25982781]

70. He H, Venema VJ, Gu X, Venema RC, Marrero MB, Caldwell RB. Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1/KDR activation of c-Src. The Journal of biological chemistry. 1999;274(35):25130–25135. [PubMed: 10455194]

71. Shen BQ, Lee DY, Zioncheck TF. Vascular endothelial growth factor governs endothelial nitric-oxide synthase expression via a KDR/Flk-1 receptor and a protein kinase C signaling pathway. The Journal of biological chemistry. 1999;274(46):33057–33063. [PubMed: 10551875]

72. Cindrova-Davies T, Sanders DA, Burton GJ, Charnock-Jones DS. Soluble FLT1 sensitizes endothelial cells to inflammatory cytokines by antagonizing VEGF receptor-mediated signalling. Cardiovascular research. 2011;89(3):671–679. [PubMed: 21139021]

73. Tsatsaris V, Goffin F, Munaut C, Brichant JF, Pignon MR, Noel A, Schaaps JP, Cabrol D, Frankenne F, Foidart JM. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. The Journal of clinical endocrinology and metabolism. 2003;88(11):5555–5563. [PubMed: 14602804]

74. Celik H, Avci B, Isik Y. Vascular endothelial growth factor and endothelin-1 levels in normal pregnant women and pregnant women with pre-eclampsia. Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology. 2013;33(4):355–358. [PubMed: 23654314]

75. Hunter A, Aitkenhead M, Caldwell C, McCracken G, Wilson D, McClure N. Serum levels of vascular endothelial growth factor in preeclamptic and normotensive pregnancy. Hypertension. 2000;36(6):965–969. [PubMed: 11116108]

76. Ahmad S, Ahmed A. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circulation research. 2004;95(9):884–891. [PubMed: 15472115]

77. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111(5):649–658. [PubMed: 12618519]

78. Masoura S, Kalogiannidis I, Makedou K, Theodoridis T, Koiou K, Gerou S, Athanasiadis A, Agorastos T. Biomarkers of endothelial dysfunction in preeclampsia and neonatal morbidity: a case-control study. European journal of obstetrics, gynecology, and reproductive biology. 2014;175:119–123.

79. Papazoglou D, Galazios G, Koukourakis MI, Kontomanolis EN, Maltezos E. Association of −634G/C and 936C/T polymorphisms of the vascular endothelial growth factor with spontaneous preterm delivery. Acta Obstet Gynecol Scand. 2004;83(5):461–465. [PubMed: 15059159]

80. George EM, Palei AC, Dent EA, Granger JP. Sildenafil attenuates placental ischemia-induced hypertension. American journal of physiology. Regulatory, integrative and comparative physiology. 2013;305(4):R397–403.

81. Stillman IE, Karumanchi SA. The glomerular injury of preeclampsia. Journal of the American Society of Nephrology : JASN. 2007;18(8):2281–2284. [PubMed: 17634433]

82. Zhu X, Wu S, Dahut WL, Parikh CR. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis. 2007;49(2):186–193. [PubMed: 17261421]

83. Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH, Gerber HP, Ferrara N, Barisoni L, Alpers CE, Quaggin SE. VEGF inhibition and renal thrombotic microangiopathy. The New England journal of medicine. 2008;358(11):1129–1136. [PubMed: 18337603]

84. Masuda Y, Shimizu A, Mori T, Ishiwata T, Kitamura H, Ohashi R, Ishizaki M, Asano G, Sugisaki Y, Yamanaka N. Vascular endothelial growth factor enhances glomerular capillary repair and accelerates resolution of experimentally induced glomerulonephritis. Am J Pathol. 2001;159(2): 599–608. [PubMed: 11485918]

85. Kim YG, Suga SI, Kang DH, Jefferson JA, Mazzali M, Gordon KL, Matsui K, Breiteneder-Geleff S, Shankland SJ, Hughes J, Kerjaschki D, Schreiner GF, Johnson RJ. Vascular endothelial growth factor accelerates renal recovery in experimental thrombotic microangiopathy. Kidney international. 2000;58(6):2390–2399. [PubMed: 11115072]

86. Hollborn M, Stathopoulos C, Steffen A, Wiedemann P, Kohen L, Bringmann A. Positive feedback regulation between MMP-9 and VEGF in human RPE cells. Invest Ophthalmol Vis Sci. 2007;48(9):4360–4367. [PubMed: 17724228]

87. Pepper MS. Extracellular proteolysis and angiogenesis. Thromb Haemost. 2001;86(1):346–355. [PubMed: 11487024]

88. Heo SH, Choi YJ, Ryoo HM, Cho JY. Expression profiling of ETS and MMP factors in VEGF-activated endothelial cells: role of MMP-10 in VEGF-induced angiogenesis. J Cell Physiol. 2010;224(3):734–742. [PubMed: 20432469]

89. Romero R, Nien JK, Espinoza J, Todem D, Fu W, Chung H, Kusanovic JP, Gotsch F, Erez O, Mazaki-Tovi S, Gomez R, Edwin S, Chaiworapongsa T, Levine RJ, Karumanchi SA. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet. 2008;21(1):9–23.

90. Krauss T, Pauer HU, Augustin HG. Prospective analysis of placenta growth factor (PlGF) concentrations in the plasma of women with normal pregnancy and pregnancies complicated by preeclampsia. Hypertension in pregnancy. 2004;23(1):101–111. [PubMed: 15117604]

91. Bian Z, Shixia C, Duan T. First-Trimester Maternal Serum Levels of sFLT1, PGF and ADMA Predict Preeclampsia. PloS one. 2015;10(4):e0124684. [PubMed: 25906026]

92. March MI, Geahchan C, Wenger J, Raghuraman N, Berg A, Haddow H, McKeon BA, Narcisse R, David JL, Scott J, Thadhani R, Karumanchi SA, Rana S. Circulating Angiogenic Factors and the Risk of Adverse Outcomes among Haitian Women with Preeclampsia. PloS one. 2015;10(5):e0126815. [PubMed: 25965397]

93. Bates DO. An unexpected tail of VEGF and PlGF in pre-eclampsia. Biochem Soc Trans. 2011;39(6):1576–1582. [PubMed: 22103490]

94. Agunanne EE, Uddin MN, Horvat D, Puschett JB. Contribution of angiogenic factors in a rat model of pre-eclampsia. Am J Nephrol. 2010;32(4):332–339. [PubMed: 20720407]

95. Morton JS, Davidge ST. Arterial endothelium-derived hyperpolarization: potential role in pregnancy adaptations and complications. Journal of cardiovascular pharmacology. 2013;61(3): 197–203. [PubMed: 23188131]

96. Mandala M, Gokina N, Barron C, Osol G. Endothelial-derived hyperpolarization factor (EDHF) contributes to PlGF-induced dilation of mesenteric resistance arteries from pregnant rats. Journal of vascular research. 2012;49(1):43–49. [PubMed: 21985802]

97. Charnock-Jones DS. Placental hypoxia, endoplasmic reticulum stress and maternal endothelial sensitisation by sFLT1 in pre-eclampsia. J Reprod Immunol. 2016;114:81–85. [PubMed: 26228018]

98. Kakigano A, Mimura K, Kanagawa T, Nakayama M, Kanayama T, Fujita S, Kinugasa-Taniguchi Y, Endo M, Tomimatsu T, Kimura T. Imbalance of angiogenic factors and avascular edematous cystic villi in a trisomy 13 pregnancy: a case report. Placenta. 2013;34(7):628–630. [PubMed: 23611482]

99. Tuzcu ZB, Asicioglu E, Sunbul M, Ozben B, Arikan H, Koc M. Circulating endothelial cell number and markers of endothelial dysfunction in previously preeclamptic women. American journal of obstetrics and gynecology. 2015;213(4):533 e531–537. [PubMed: 26116870]

100. Palmer KR, Kaitu'u-Lino TJ, Hastie R, Hannan NJ, Ye L, Binder N, Cannon P, Tuohey L, Johns TG, Shub A, Tong S. Placental-Specific sFLT-1 e15a Protein Is Increased in Preeclampsia, Antagonizes Vascular Endothelial Growth Factor Signaling, and Has Antiangiogenic Activity. Hypertension. 2015;66(6):1251–1259. [PubMed: 26416849]

101. Noori M, Donald AE, Angelakopoulou A, Hingorani AD, Williams DJ. Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension. Circulation. 2010;122(5):478–487. [PubMed: 20644016]

102. Bdolah Y, Lam C, Rajakumar A, Shivalingappa V, Mutter W, Sachs BP, Lim KH, Bdolah-Abram T, Epstein FH, Karumanchi SA. Twin pregnancy and the risk of preeclampsia: bigger placenta or relative ischemia? American journal of obstetrics and gynecology. 2008;198(4):428 e421–426. [PubMed: 18191808]

103. Faupel-Badger JM, McElrath TF, Lauria M, Houghton LC, Lim KH, Parry S, Cantonwine D, Lai G, Karumanchi SA, Hoover RN, Troisi R. Maternal circulating angiogenic factors in twin and singleton pregnancies. American journal of obstetrics and gynecology. 2015;212(5):636 e631–638. [PubMed: 25434840]

104. Verdonk K, Saleh L, Lankhorst S, Smilde JE, van Ingen MM, Garrelds IM, Friesema EC, Russcher H, van den Meiracker AH, Visser W, Danser AH. Association studies suggest a key role for endothelin-1 in the pathogenesis of preeclampsia and the accompanying renin-angiotensin-aldosterone system suppression. Hypertension. 2015;65(6):1316–1323. [PubMed: 25870197]

105. Thadhani R, Hagmann H, Schaarschmidt W, Roth B, Cingoez T, Karumanchi SA, Wenger J, Lucchesi KJ, Tamez H, Lindner T, Fridman A, Thome U, Kribs A, Danner M, Hamacher S, Mallmann P, Stepan H, Benzing T. Removal of Soluble Fms-Like Tyrosine Kinase-1 by Dextran Sulfate Apheresis in Preeclampsia. Journal of the American Society of Nephrology : JASN. 2016;27(3):903–913. [PubMed: 26405111]

106. Zhu M, Ren Z, Possomato-Vieira JS, Khalil RA. Restoring placental growth factor-soluble fms-like tyrosine kinase-1 balance reverses vascular hyper-reactivity and hypertension in pregnancy. American journal of physiology. Regulatory, integrative and comparative physiology. 2016;311(3):R505–521.

107. Ramesar SV, Mackraj I, Gathiram P, Moodley J. Sildenafil citrate decreases sFlt-1 and sEng in pregnant l-NAME treated Sprague-Dawley rats. European journal of obstetrics, gynecology, and reproductive biology. 2011;157(2):136–140.

108. Gillis EE, Williams JM, Garrett MR, Mooney JN, Sasser JM. The Dahl salt-sensitive rat is a spontaneous model of superimposed preeclampsia. American journal of physiology. Regulatory, integrative and comparative physiology. 2015;309(1):R62–70.

109. Siddiqui AH, Irani RA, Zhang W, Wang W, Blackwell SC, Kellems RE, Xia Y. Angiotensin receptor agonistic autoantibody-mediated soluble fms-like tyrosine kinase-1 induction contributes to impaired adrenal vasculature and decreased aldosterone production in preeclampsia. Hypertension. 2013;61(2):472–479. [PubMed: 23283357]

110. Sunderland NS, Thomson SE, Heffernan SJ, Lim S, Thompson J, Ogle R, McKenzie P, Kirwan PJ, Makris A, Hennessy A. Tumor necrosis factor alpha induces a model of preeclampsia in pregnant baboons (Papio hamadryas). Cytokine. 2011;56(2):192–199. [PubMed: 21737300]

111. Bobek G, Surmon L, Mirabito KM, Makris A, Hennessy A. Placental Regulation of Inflammation and Hypoxia after TNF-alpha Infusion in Mice. American journal of reproductive immunology. 2015;74(5):407–418. [PubMed: 26220019]

112. Li Z, Zhang Y, Ying Ma J, Kapoun AM, Shao Q, Kerr I, Lam A, O'Young G, Sannajust F, Stathis P, Schreiner G, Karumanchi SA, Protter AA, Pollitt NS. Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension. 2007;50(4):686–692. [PubMed: 17724276]

113. Amraoui F, Spijkers L, Hassani Lahsinoui H, Vogt L, van der Post J, Peters S, Afink G, Ris-Stalpers C, van den Born BJ. SFlt-1 elevates blood pressure by augmenting endothelin-1-mediated vasoconstriction in mice. PloS one. 2014;9(3):e91897. [PubMed: 24632840]

114. Fan X, Rai A, Kambham N, Sung JF, Singh N, Petitt M, Dhal S, Agrawal R, Sutton RE, Druzin ML, Gambhir SS, Ambati BK, Cross JC, Nayak NR. Endometrial VEGF induces placental sFLT1 and leads to pregnancy complications. The Journal of clinical investigation. 2014;124(11): 4941–4952. [PubMed: 25329693]

115. Adya R, Tan BK, Punn A, Chen J, Randeva HS. Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis. Cardiovasc Res. 2008;78(2):356–365. [PubMed: 18093986]

116. Kaneko H, Anzai T, Takahashi T, Kohno T, Shimoda M, Sasaki A, Shimizu H, Nagai T, Maekawa Y, Yoshimura K, Aoki H, Yoshikawa T, Okada Y, Yozu R, Ogawa S, Fukuda K. Role of vascular endothelial growth factor-A in development of abdominal aortic aneurysm. Cardiovasc Res. 2011;91(2):358–367. [PubMed: 21436157]

117. Gilbert JS, Verzwyvelt J, Colson D, Arany M, Karumanchi SA, Granger JP. Recombinant vascular endothelial growth factor 121 infusion lowers blood pressure and improves renal function in rats with placentalischemia-induced hypertension. Hypertension. 2010;55(2):380–385. [PubMed: 20026764]

118. Luft FC. Soluble endoglin (sEng) joins the soluble fms-like tyrosine kinase (sFlt) receptor as a pre-eclampsia molecule. Nephrol Dial Transplant. 2006;21(11):3052–3054. [PubMed: 16870672]

119. Maynard S, Epstein FH, Karumanchi SA. Preeclampsia and angiogenic imbalance. Annual review of medicine. 2008;59:61–78.

120. Yinon Y, Nevo O, Xu J, Many A, Rolfo A, Todros T, Post M, Caniggia I. Severe intrauterine growth restriction pregnancies have increased placental endoglin levels: hypoxic regulation via transforming growth factor-beta 3. Am J Pathol. 2008;172(1):77–85. [PubMed: 18156205]

121. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, Bdolah Y, Lim KH, Yuan HT, Libermann TA, Stillman IE, Roberts D, D'Amore PA, Epstein FH, Sellke FW, Romero R, Sukhatme VP, Letarte M, Karumanchi SA. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006;12(6):642–649. [PubMed: 16751767]

122. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi SA. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. The New England journal of medicine. 2006;355(10):992–1005. [PubMed: 16957146]

123. Ramma W, Buhimschi IA, Zhao G, Dulay AT, Nayeri UA, Buhimschi CS, Ahmed A. The elevation in circulating anti-angiogenic factors is independent of markers of neutrophil activation in preeclampsia. Angiogenesis. 2012;15(3):333–340. [PubMed: 22398973]

124. Morris R, Spencer SK, Kyle PB, Williams JM, Harris A, Owens MY, Wallace K. Hypertension in an Animal Model of HELLP Syndrome is Associated With Activation of Endothelin 1. Reproductive sciences. 2015;23(1):42–50. [PubMed: 26130680]

125. Hawinkels LJ, Kuiper P, Wiercinska E, Verspaget HW, Liu Z, Pardali E, Sier CF, ten Dijke P. Matrix metalloproteinase-14 (MT1-MMP)-mediated endoglin shedding inhibits tumor angiogenesis. Cancer Res. 2010;70(10):4141–4150. [PubMed: 20424116]

126. LaMarca B, Speed J, Fournier L, Babcock SA, Berry H, Cockrell K, Granger JP. Hypertension in response to chronic reductions in uterine perfusion in pregnant rats: effect of tumor necrosis factor-alpha blockade. Hypertension. 2008;52(6):1161–1167. [PubMed: 18981324]

127. Moreno-Eutimio MA, Tovar-Rodriguez JM, Vargas-Avila K, Nieto-Velazquez NG, Frias-De-Leon MG, Sierra-Martinez M, Acosta-Altamirano G. Increased serum levels of inflammatory mediators and low frequency of regulatory T cells in the peripheral blood of preeclamptic Mexican women. BioMed research international. 2014;2014:413249. [PubMed: 25574467]

128. Pinheiro MB, Gomes KB, Ronda CR, Guimaraes GG, Freitas LG, Teixeira-Carvalho A, Martins-Filho OA, Dusse LM. Severe preeclampsia: association of genes polymorphisms and maternal cytokines production in Brazilian population. Cytokine. 2015;71(2):232–237. [PubMed: 25461403]

129. Peixoto AB, Araujo Junior E, Ribeiro JU, Rodrigues DB, Castro EC, Caldas TM, Rodrigues Junior V. Evaluation of inflammatory mediators in the deciduas of pregnant women with pre-eclampsia/eclampsia. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet. 2016;29(1):75–79.

130. Wang W, Parchim NF, Iriyama T, Luo R, Zhao C, Liu C, Irani RA, Zhang W, Ning C, Zhang Y, Blackwell SC, Chen L, Tao L, Hicks MJ, Kellems RE, Xia Y. Excess LIGHT contributes to placental impairment, increased secretion of vasoactive factors, hypertension, and proteinuria in preeclampsia. Hypertension. 2014;63(3):595–606. [PubMed: 24324043]

131. Wallace K, Richards S, Dhillon P, Weimer A, Edholm ES, Bengten E, Wilson M, Martin JN Jr., LaMarca B. CD4+ T-helper cells stimulated in response to placental ischemia mediate hypertension during pregnancy. Hypertension. 2011;57(5):949–955. [PubMed: 21464392]

132. Cornelius DC, Amaral LM, Harmon A, Wallace K, Thomas AJ, Campbell N, Scott J, Herse F, Haase N, Moseley J, Wallukat G, Dechend R, LaMarca B. An increased population of regulatory T cells improves the pathophysiology of placental ischemia in a rat model of preeclampsia. American journal of physiology. Regulatory, integrative and comparative physiology. 2015;309(8):R884–891.

133. Alexander BT, Cockrell KL, Massey MB, Bennett WA, Granger JP. Tumor necrosis factor-alpha-induced hypertension in pregnant rats results in decreased renal neuronal nitric oxide synthase expression. American journal of hypertension. 2002;15(2 Pt 1):170–175.

134. Sanchez-Aranguren LC, Prada CE, Riano-Medina CE, Lopez M. Endothelial dysfunction and preeclampsia: role of oxidative stress. Frontiers in physiology. 2014;5:372. [PubMed: 25346691]

135. Palei AC, Granger JP, Tanus-Santos JE. Matrix metalloproteinases as drug targets in preeclampsia. Current drug targets. 2013;14(3):325–334. [PubMed: 23316964]

136. Lamarca B, Brewer J, Wallace K. IL-6-induced pathophysiology during pre-eclampsia: potential therapeutic role for magnesium sulfate? International journal of interferon, cytokine and mediator research : IJIM. 2011;2011(3):59–64.

137. Lockwood CJ, Yen CF, Basar M, Kayisli UA, Martel M, Buhimschi I, Buhimschi C, Huang SJ, Krikun G, Schatz F. Preeclampsia-related inflammatory cytokines regulate interleukin-6 expression in human decidual cells. Am J Pathol. 2008;172(6):1571–1579. [PubMed: 18467705]

138. Matias ML, Romao M, Weel IC, Ribeiro VR, Nunes PR, Borges VT, Araujo JP Jr., Peracoli JC, de Oliveira L, Peracoli MT. Endogenous and Uric Acid-Induced Activation of NLRP3 Inflammasome in Pregnant Women with Preeclampsia. PloS one. 2015;10(6):e0129095. [PubMed: 26053021]

139. Royle C, Lim S, Xu B, Tooher J, Ogle R, Hennessy A. Effect of hypoxia and exogenous IL-10 on the pro-inflammatory cytokine TNF-alpha and the anti-angiogenic molecule soluble Flt-1 in placental villous explants. Cytokine. 2009;47(1):56–60. [PubMed: 19501525]

140. Rahardjo B, Widjajanto E, Sujuti H, Keman K. Different levels of IL-1alpha, IL-6, TNF-alpha, NF-kappaB and PPAR-gamma in monocyte cultures exposed by plasma preeclampsia and normotensive pregnancy. Pregnancy hypertension. 2014;4(3):187–193. [PubMed: 26104604]

141. Palei AC, Spradley FT, Warrington JP, George EM, Granger JP. Pathophysiology of hypertension in pre-eclampsia: a lesson in integrative physiology. Acta Physiol (Oxf). 2013;208(3):224–233. [PubMed: 23590594]

142. Daikoku T, Matsumoto H, Gupta RA, Das SK, Gassmann M, DuBois RN, Dey SK. Expression of hypoxia-inducible factors in the peri-implantation mouse uterus is regulated in a cell-specific and ovarian steroid hormone-dependent manner. Evidence for differential function of HIFs during early pregnancy. J Biol Chem. 2003;278(9):7683–7691. [PubMed: 12482866]

143. Patel J, Landers K, Mortimer RH, Richard K. Regulation of hypoxia inducible factors (HIF) in hypoxia and normoxia during placental development. Placenta. 2010;31(11):951–957. [PubMed: 20869770]

144. Akhilesh M, Mahalingam V, Nalliah S, Ali RM, Ganesalingam M, Haleagrahara N. Hypoxia-inducible factor-1alpha as a predictive marker in pre-eclampsia. Biomed Rep. 2013;1(2):257–258. [PubMed: 24648931]

145. Tal R The role of hypoxia and hypoxia-inducible factor-1alpha in preeclampsia pathogenesis. Biology of reproduction. 2012;87(6):134. [PubMed: 23034156]

146. Iriyama T, Wang W, Parchim NF, Song A, Blackwell SC, Sibai BM, Kellems RE, Xia Y. Hypoxia-independent upregulation of placental hypoxia inducible factor-1alpha gene expression contributes to the pathogenesis of preeclampsia. Hypertension. 2015;65(6):1307–1315. [PubMed: 25847948]

147. Semenza GL. Regulation of oxygen homeostasis by hypoxia-inducible factor 1. Physiology (Bethesda). 2009;24:97–106. [PubMed: 19364912]

148. Gaber T, Dziurla R, Tripmacher R, Burmester GR, Buttgereit F. Hypoxia inducible factor (HIF) in rheumatology: low O2! See what HIF can do! Ann Rheum Dis. 2005;64(7):971–980. [PubMed: 15800008]

149. Milkiewicz M, Doyle JL, Fudalewski T, Ispanovic E, Aghasi M, Haas TL. HIF-1alpha and HIF-2alpha play a central role in stretch-induced but not shear-stress-induced angiogenesis in rat skeletal muscle. J Physiol. 2007;583(Pt 2):753–766. [PubMed: 17627993]

150. Milkiewicz M, Haas TL. Effect of mechanical stretch on HIF-1{alpha} and MMP-2 expression in capillaries isolated from overloaded skeletal muscles: laser capture microdissection study. Am J Physiol Heart Circ Physiol. 2005;289(3):H1315–1320. [PubMed: 15894575]

151. Chang H, Shyu KG, Wang BW, Kuan P. Regulation of hypoxia-inducible factor-1alpha by cyclical mechanical stretch in rat vascular smooth muscle cells. Clin Sci (Lond). 2003;105(4):447–456. [PubMed: 12780343]

152. Kim CH, Cho YS, Chun YS, Park JW, Kim MS. Early expression of myocardial HIF-1alpha in response to mechanical stresses: regulation by stretch-activated channels and the phosphatidylinositol 3-kinase signaling pathway. Circ Res. 2002;90(2):E25–33. [PubMed: 11834720]

153. Petersen W, Varoga D, Zantop T, Hassenpflug J, Mentlein R, Pufe T. Cyclic strain influences the expression of the vascular endothelial growth factor (VEGF) and the hypoxia inducible factor 1 alpha (HIF-1alpha) in tendon fibroblasts. J Orthop Res. 2004;22(4):847–853. [PubMed: 15183444]

154. Lee JD, Jeng SY, Lee TH. Increased expression of hypoxia-inducible factor-1alpha in the internal spermatic vein of patients with varicocele. J Urol. 2006;175(3 Pt 1):1045–1048; discussion 1048. [PubMed: 16406902]

155. Fujiwara S, Nakagawa K, Harada H, Nagato S, Furukawa K, Teraoka M, Seno T, Oka K, Iwata S, Ohnishi T. Silencing hypoxia-inducible factor-1alpha inhibits cell migration and invasion under hypoxic environment in malignant gliomas. Int J Oncol. 2007;30(4):793–802. [PubMed: 17332917]

156. Lim CS, Qiao X, Reslan OM, Xia Y, Raffetto JD, Paleolog E, Davies AH, Khalil RA. Prolonged mechanical stretch is associated with upregulation of hypoxia-inducible factors and reduced contraction in rat inferior vena cava. J Vasc Surg. 2011;53(3):764–773. [PubMed: 21106323]

157. Myatt L, Webster RP. Vascular biology of preeclampsia. Journal of thrombosis and haemostasis : JTH. 2009;7(3):375–384. [PubMed: 19087223]

158. Nakamura M, Sekizawa A, Purwosunu Y, Okazaki S, Farina A, Wibowo N, Shimizu H, Okai T. Cellular mRNA expressions of anti-oxidant factors in the blood of preeclamptic women. Prenat Diagn. 2009;29(7):691–696. [PubMed: 19399816]

159. Sikorski EM, Hock T, Hill-Kapturczak N, Agarwal A. The story so far: Molecular regulation of the heme oxygenase-1 gene in renal injury. Am J Physiol Renal Physiol. 2004;286(3):F425–441. [PubMed: 14761930]

160. Dulak J, Deshane J, Jozkowicz A, Agarwal A. Heme oxygenase-1 and carbon monoxide in vascular pathobiology: focus on angiogenesis. Circulation. 2008;117(2):231–241. [PubMed: 18195184]

161. Yachie A, Niida Y, Wada T, Igarashi N, Kaneda H, Toma T, Ohta K, Kasahara Y, Koizumi S. Oxidative stress causes enhanced endothelial cell injury in human heme oxygenase-1 deficiency. The Journal of clinical investigation. 1999;103(1):129–135. [PubMed: 9884342]

162. Turpin CA, Sakyi SA, Owiredu WK, Ephraim RK, Anto EO. Association between adverse pregnancy outcome and imbalance in angiogenic regulators and oxidative stress biomarkers in gestational hypertension and preeclampsia. BMC Pregnancy Childbirth. 2015;15:189. [PubMed: 26303772]

163. Reslan OM, Khalil RA. Molecular and vascular targets in the pathogenesis and management of the hypertension associated with preeclampsia. Cardiovascular & hematological agents in medicinal chemistry. 2010;8(4):204–226. [PubMed: 20923405]

164. Cohen JM, Kramer MS, Platt RW, Basso O, Evans RW, Kahn SR. The association between maternal antioxidant levels in midpregnancy and preeclampsia. American journal of obstetrics and gynecology. 2015;213(5):695 e691–695 e613. [PubMed: 26215330]

165. Chambers JC, Fusi L, Malik IS, Haskard DO, De Swiet M, Kooner JS. Association of maternal endothelial dysfunction with preeclampsia. Jama. 2001;285(12):1607–1612. [PubMed: 11268269]

166. Peracoli MT, Bannwart CF, Cristofalo R, Borges VT, Costa RA, Witkin SS, Peracoli JC. Increased reactive oxygen species and tumor necrosis factor-alpha production by monocytes are associated with elevated levels of uric acid in pre-eclamptic women. American journal of reproductive immunology. 2011;66(6):460–467. [PubMed: 21623992]

167. Tsukimori K, Fukushima K, Tsushima A, Nakano H. Generation of reactive oxygen species by neutrophils and endothelial cell injury in normal and preeclamptic pregnancies. Hypertension. 2005;46(4):696–700. [PubMed: 16172429]

168. Cui XL, Brockman D, Campos B, Myatt L. Expression of NADPH oxidase isoform 1 (Nox1) in human placenta: involvement in preeclampsia. Placenta. 2006;27(4–5):422–431. [PubMed: 15993942]

169. Matsubara K, Matsubara Y, Hyodo S, Katayama T, Ito M. Role of nitric oxide and reactive oxygen species in the pathogenesis of preeclampsia. The journal of obstetrics and gynaecology research. 2010;36(2):239–247. [PubMed: 20492372]

170. Amaral LM, Pinheiro LC, Guimaraes DA, Palei AC, Sertorio JT, Portella RL, Tanus-Santos JE. Antihypertensive effects of inducible nitric oxide synthase inhibition in experimental pre-eclampsia. J Cell Mol Med. 2013;17(10):1300–1307. [PubMed: 23890248]

171. Mitchell BM, Cook LG, Danchuk S, Puschett JB. Uncoupled endothelial nitric oxide synthase and oxidative stress in a rat model of pregnancy-induced hypertension. American journal of hypertension. 2007;20(12):1297–1304. [PubMed: 18047920]

172. Genc H, Uzun H, Benian A, Simsek G, Gelisgen R, Madazli R, Guralp O. Evaluation of oxidative stress markers in first trimester for assessment of preeclampsia risk. Archives of gynecology and obstetrics. 2011;284(6):1367–1373. [PubMed: 21344259]

173. Cross CE, Tolba MF, Rondelli CM, Xu M, Abdel-Rahman SZ. Oxidative Stress Alters miRNA and Gene Expression Profiles in Villous First Trimester Trophoblasts. BioMed research international. 2015;2015:257090. [PubMed: 26339600]

174. Weinberger MH, Kramer NJ, Petersen LP, Cleary RE, Young PC. Sequential changes in the renin--angiotensin--aldosterone systems and plasma progesterone concentration in normal and abnormal human pregnancy. Perspect Nephrol Hypertens. 1976;5:263–269. [PubMed: 1005040]

175. August P, Lenz T, Ales KL, Druzin ML, Edersheim TG, Hutson JM, Muller FB, Laragh JH, Sealey JE. Longitudinal study of the renin-angiotensin-aldosterone system in hypertensive pregnant women: deviations related to the development of superimposed preeclampsia. American journal of obstetrics and gynecology. 1990;163(5 Pt 1):1612–1621.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

176. Gant NF, Daley GL, Chand S, Whalley PJ, MacDonald PC. A study of angiotensin II pressor response throughout primigravid pregnancy. The Journal of clinical investigation. 1973;52(11): 2682–2689. [PubMed: 4355997]

177. Anton L, Merrill DC, Neves LA, Stovall K, Gallagher PE, Diz DI, Moorefield C, Gruver C, Ferrario CM, Brosnihan KB. Activation of local chorionic villi angiotensin II levels but not angiotensin (1–7) in preeclampsia. Hypertension. 2008;51(4):1066–1072. [PubMed: 18259034]

178. Mistry HD, Kurlak LO, Broughton Pipkin F. The placental renin-angiotensin system and oxidative stress in pre-eclampsia. Placenta. 2013;34(2):182–186. [PubMed: 23246097]

179. Bakker WW, Henning RH, van Son WJ, van Pampus MG, Aarnoudse JG, Niezen-Koning KE, Borghuis T, Jongman RM, van Goor H, Poelstra K, Navis G, Faas MM. Vascular contraction and preeclampsia: downregulation of the Angiotensin receptor 1 by hemopexin in vitro. Hypertension. 2009;53(6):959–964. [PubMed: 19414647]

180. Bai K, Wang K, Li X, Wang J, Zhang J, Song L, Zhang S, Lau WB, Ma X, Liu H. Autoantibody against angiotensin AT1 receptor from preeclamptic patients enhances collagen-induced human platelet aggregation. Acta Biochim Biophys Sin (Shanghai). 2013;45(9):749–755. [PubMed: 23681235]

181. Yang J, Li L, Shang JY, Cai L, Song L, Zhang SL, Li H, Li X, Lau WB, Ma XL, Liu HR. Angiotensin II type 1 receptor autoantibody as a novel regulator of aldosterone independent of preeclampsia. Journal of hypertension. 2015;33(5):1046–1056. [PubMed: 25693057]

182. Xia Y, Ramin SM, Kellems RE. Potential roles of angiotensin receptor-activating autoantibody in the pathophysiology of preeclampsia. Hypertension. 2007;50(2):269–275. [PubMed: 17576854]

183. Zhou CC, Zhang Y, Irani RA, Zhang H, Mi T, Popek EJ, Hicks MJ, Ramin SM, Kellems RE, Xia Y. Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice. Nat Med. 2008;14(8):855–862. [PubMed: 18660815]

184. Yang X, Wang F, Lau WB, Zhang S, Liu H, Ma XL. Autoantibodies isolated from preeclamptic patients induce endothelial dysfunction via interaction with the angiotensin II AT1 receptor. Cardiovasc Toxicol. 2014;14(1):21–29. [PubMed: 24122090]

185. Novotny SR, Wallace K, Heath J, Moseley J, Dhillon P, Weimer A, Wallukat G, Herse F, Wenzel K, Martin JN Jr., Dechend R, Lamarca B. Activating autoantibodies to the angiotensin II type I receptor play an important role in mediating hypertension in response to adoptive transfer of CD4+ T lymphocytes from placental ischemic rats. American journal of physiology. Regulatory, integrative and comparative physiology. 2012;302(10):R1197–1201.

186. LaMarca B, Wallukat G, Llinas M, Herse F, Dechend R, Granger JP. Autoantibodies to the angiotensin type I receptor in response to placental ischemia and tumor necrosis factor alpha in pregnant rats. Hypertension. 2008;52(6):1168–1172. [PubMed: 18852381]

187. LaMarca B, Parrish M, Ray LF, Murphy SR, Roberts L, Glover P, Wallukat G, Wenzel K, Cockrell K, Martin JN Jr., Ryan MJ, Dechend R. Hypertension in response to autoantibodies to the angiotensin II type I receptor (AT1-AA) in pregnant rats: role of endothelin-1. Hypertension. 2009;54(4):905–909. [PubMed: 19704104]

188. Parrish MR, Ryan MJ, Glover P, Brewer J, Ray L, Dechend R, Martin JN Jr., Lamarca BB. Angiotensin II type 1 autoantibody induced hypertension during pregnancy is associated with renal endothelial dysfunction. Gender medicine. 2011;8(3):184–188. [PubMed: 21600854]

189. Escudero CA, Herlitz K, Troncoso F, Acurio J, Aguayo C, Roberts JM, Truong G, Duncombe G, Rice G, Salomon C. Role of Extracellular Vesicles and microRNAs on Dysfunctional Angiogenesis during Preeclamptic Pregnancies. Frontiers in physiology. 2016;7:98. [PubMed: 27047385]

190. Conrad KP. Maternal vasodilation in pregnancy: the emerging role of relaxin. Am J Physiol Regul Integr Comp Physiol. 2011;301(2):R267–275. [PubMed: 21613576]

191. Crews JK, Novak J, Granger JP, Khalil RA. Stimulated mechanisms of Ca2+ entry into vascular smooth muscle during NO synthesis inhibition in pregnant rats. Am J Physiol. 1999;276(2 Pt 2):R530–538.

192. Risberg A, Olsson K, Lyrenas S, Sjoquist M. Plasma vasopressin, oxytocin, estradiol, and progesterone related to water and sodium excretion in normal pregnancy and gestational hypertension. Acta Obstet Gynecol Scand. 2009;88(6):639–646. [PubMed: 19412798]

193. Crews JK, Khalil RA. Gender-specific inhibition of Ca2+ entry mechanisms of arterial vasoconstriction by sex hormones. Clin Exp Pharmacol Physiol. 1999;26(9):707–715. [PubMed: 10499160]

194. Scott PA, Tremblay A, Brochu M, St-Louis J. Vasorelaxant action of 17 -estradiol in rat uterine arteries: role of nitric oxide synthases and estrogen receptors. Am J Physiol Heart Circ Physiol. 2007;293(6):H3713–3719. [PubMed: 17951367]

195. Brandao AH, Felix LR, Patricio Edo C, Leite HV, Cabral AC. Difference of endothelial function during pregnancies as a method to predict preeclampsia. Archives of gynecology and obstetrics. 2014;290(3):471–477. [PubMed: 24748339]

196. Sierra-Laguado J, Garcia RG, Lopez-Jaramillo P. Flow-mediated dilatation of the brachial artery in pregnancy. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2006;93(1):60–61.

197. Knock GA, Poston L. Bradykinin-mediated relaxation of isolated maternal resistance arteries in normal pregnancy and preeclampsia. American journal of obstetrics and gynecology. 1996;175(6):1668–1674. [PubMed: 8987958]

198. Yi FX, Boeldt DS, Gifford SM, Sullivan JA, Grummer MA, Magness RR, Bird IM. Pregnancy enhances sustained Ca2+ bursts and endothelial nitric oxide synthase activation in ovine uterine artery endothelial cells through increased connexin 43 function. Biology of reproduction. 2010;82(1):66–75. [PubMed: 19741206]

199. Hu XQ, Xiao D, Zhu R, Huang X, Yang S, Wilson S, Zhang L. Pregnancy upregulates large-conductance Ca(2+)-activated K(+) channel activity and attenuates myogenic tone in uterine arteries. Hypertension. 2011;58(6):1132–1139. [PubMed: 22042813]

200. Reslan OM, Khalil RA. Vascular effects of estrogenic menopausal hormone therapy. Rev Recent Clin Trials. 2012;7(1):47–70. [PubMed: 21864249]

201. Kanashiro CA, Khalil RA. Gender-related distinctions in protein kinase C activity in rat vascular smooth muscle. Am J Physiol Cell Physiol. 2001;280(1):C34–45. [PubMed: 11121374]

202. Murphy JG, Khalil RA. Decreased [Ca(2+)](i) during inhibition of coronary smooth muscle contraction by 17beta-estradiol, progesterone, and testosterone. J Pharmacol Exp Ther. 1999;291(1):44–52. [PubMed: 10490885]

203. Crews JK, Khalil RA. Antagonistic effects of 17 beta-estradiol, progesterone, and testosterone on Ca2+ entry mechanisms of coronary vasoconstriction. Arterioscler Thromb Vasc Biol. 1999;19(4):1034–1040. [PubMed: 10195933]

204. Guimaraes MF, Brandao AH, Rezende CA, Cabral AC, Brum AP, Leite HV, Capuruco CA. Assessment of endothelial function in pregnant women with preeclampsia and gestational diabetes mellitus by flow-mediated dilation of brachial artery. Archives of gynecology and obstetrics. 2014;290(3):441–447. [PubMed: 24691824]

205. Yoshida A, Nakao S, Kobayashi M, Kobayashi H. Flow-mediated vasodilation and plasma fibronectin levels in preeclampsia. Hypertension. 2000;36(3):400–404. [PubMed: 10988272]

206. Canbakan B, Keven K, Tutkak H, Danisman N, Ergun I, Nergizoglu G. Circulating endothelial cells in preeclampsia. Journal of human hypertension. 2007;21(7):558–563. [PubMed: 17429447]

207. Adekola H, Romero R, Chaemsaithong P, Korzeniewski SJ, Dong Z, Yeo L, Hassan SS, Chaiworapongsa T. Endocan, a putative endothelial cell marker, is elevated in preeclampsia, decreased in acute pyelonephritis, and unchanged in other obstetrical syndromes. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet. 2015;28(14):1621–1632.

208. Cakmak M, Yilmaz H, Baglar E, Darcin T, Inan O, Aktas A, Celik HT, Ozdemir O, Atalay CR, Akcay A. Serum levels of endocan correlate with the presence and severity of pre-eclampsia. Clinical and experimental hypertension. 2016;38(2):137–142. [PubMed: 26418319]

209. Sakashita T, Higashi Y, Soga J, Miyoshi H, Kudo Y. Circulating endothelial progenitor cells and placental abruption in women with preeclampsia. Pregnancy hypertension. 2014;4(3):203–208. [PubMed: 26104606]

210. Amaral LM, Cornelius DC, Harmon A, Moseley J, Martin JN Jr., LaMarca B. 17-hydroxyprogesterone caproate significantly improves clinical characteristics of preeclampsia in

the reduced uterine perfusion pressure rat model. Hypertension. 2015;65(1):225–231. [PubMed: 25368030]

211. Alexander BT, Kassab SE, Miller MT, Abram SR, Reckelhoff JF, Bennett WA, Granger JP. Reduced uterine perfusion pressure during pregnancy in the rat is associated with increases in arterial pressure and changes in renal nitric oxide. Hypertension. 2001;37(4):1191–1195. [PubMed: 11304523]

212. Mazzuca MQ, Li W, Reslan OM, Yu P, Mata KM, Khalil RA. Downregulation of microvascular endothelial type B endothelin receptor is a central vascular mechanism in hypertensive pregnancy. Hypertension. 2014;64(3):632–643. [PubMed: 24914193]

213. Shaamash AH, Elsnosy ED, Makhlouf AM, Zakhari MM, Ibrahim OA, HM EL-d. Maternal and fetal serum nitric oxide (NO) concentrations in normal pregnancy, pre-eclampsia and eclampsia. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2000;68(3):207–214.

214. Nelson SH, Steinsland OS, Wang Y, Yallampalli C, Dong YL, Sanchez JM. Increased nitric oxide synthase activity and expression in the human uterine artery during pregnancy. Circulation research. 2000;87(5):406–411. [PubMed: 10969039]

215. Dotsch J, Hogen N, Nyul Z, Hanze J, Knerr I, Kirschbaum M, Rascher W. Increase of endothelial nitric oxide synthase and endothelin-1 mRNA expression in human placenta during gestation. European journal of obstetrics, gynecology, and reproductive biology. 2001;97(2):163–167.

216. Alexander BT, Miller MT, Kassab S, Novak J, Reckelhoff JF, Kruckeberg WC, Granger JP. Differential expression of renal nitric oxide synthase isoforms during pregnancy in rats. Hypertension. 1999;33(1 Pt 2):435–439.

217. Alpoim PN, Gomes KB, Pinheiro Mde B, Godoi LC, Jardim LL, Muniz LG, Sandrim VC, Fernandes AP, Dusse LM. Polymorphisms in endothelial nitric oxide synthase gene in early and late severe preeclampsia. Nitric oxide : biology and chemistry / official journal of the Nitric Oxide Society. 2014;42:19–23.

218. Ben Ali Gannoun M, Zitouni H, Raguema N, Maleh W, Gris JC, Almawi W, Mahjoub T. Association of common eNOS/NOS3 polymorphisms with preeclampsia in Tunisian Arabs. Gene. 2015;569(2):303–307. [PubMed: 26049094]

219. Leonardo DP, Albuquerque DM, Lanaro C, Baptista LC, Cecatti JG, Surita FG, Parpinelli MA, Costa FF, Franco-Penteado CF, Fertrin KY, Costa ML. Association of Nitric Oxide Synthase and Matrix Metalloprotease Single Nucleotide Polymorphisms with Preeclampsia and Its Complications. PloS one. 2015;10(8):e0136693. [PubMed: 26317342]

220. Sandrim VC, Palei AC, Sertorio JT, Cavalli RC, Duarte G, Tanus-Santos JE. Effects of eNOS polymorphisms on nitric oxide formation in healthy pregnancy and in pre-eclampsia. Molecular human reproduction. 2010;16(7):506–510. [PubMed: 20457799]

221. Echeverri I, Ortega-Avila JG, Mosquera M, Castillo A, Jimenez E, Suarez-Ortegon MF, Mateus JC, Aguilar-de Plata C. Relationship between maternal and newborn endothelial function and oxidative stress. American journal of human biology : the official journal of the Human Biology Council. 2015;27(6):822–831. [PubMed: 25945813]

222. Noorbakhsh M, Kianpour M, Nematbakhsh M. Serum levels of asymmetric dimethylarginine, vascular endothelial growth factor, and nitric oxide metabolite levels in preeclampsia patients. ISRN obstetrics and gynecology. 2013;2013:104213. [PubMed: 24109515]

223. Schiessl B, Strasburger C, Bidlingmaier M, Mylonas I, Jeschke U, Kainer F, Friese K. Plasma- and urine concentrations of nitrite/nitrate and cyclic Guanosinemonophosphate in intrauterine growth restricted and preeclamptic pregnancies. Archives of gynecology and obstetrics. 2006;274(3):150–154. [PubMed: 16532320]

224. Pimentel AM, Pereira NR, Costa CA, Mann GE, Cordeiro VS, de Moura RS, Brunini TM, Mendes-Ribeiro AC, Resende AC. L-arginine-nitric oxide pathway and oxidative stress in plasma and platelets of patients with pre-eclampsia. Hypertension research : official journal of the Japanese Society of Hypertension. 2013;36(9):783–788. [PubMed: 23575380]

225. Ehsanipoor RM, Fortson W, Fitzmaurice LE, Liao WX, Wing DA, Chen DB, Chan K. Nitric oxide and carbon monoxide production and metabolism in preeclampsia. Reproductive sciences. 2013;20(5):542–548. [PubMed: 23012314]

226. Conrad KP, Kerchner LJ, Mosher MD. Plasma and 24-h NO(x) and cGMP during normal pregnancy and preeclampsia in women on a reduced NO(x) diet. The American journal of physiology. 1999;277(1 Pt 2):F48–57.

227. Bhavina K, Radhika J, Pandian SS. VEGF and eNOS expression in umbilical cord from pregnancy complicated by hypertensive disorder with different severity. BioMed research international. 2014;2014:982159. [PubMed: 24959596]

228. Wang L, Yang T, Ding Y, Zhong Y, Yu L, Peng M. Chemerin plays a protective role by regulating human umbilical vein endothelial cell-induced nitric oxide signaling in preeclampsia. Endocrine. 2015;48(1):299–308. [PubMed: 24840719]

229. Zawiejska A, Wender-Ozegowska E, Iciek R, Brazert J. Concentrations of endothelial nitric oxide synthase, angiotensin-converting enzyme, vascular endothelial growth factor and placental growth factor in maternal blood and maternal metabolic status in pregnancy complicated by hypertensive disorders. Journal of human hypertension. 2014;28(11):670–676. [PubMed: 25186136]

230. Smith-Jackson K, Hentschke MR, Poli-de-Figueiredo CE, Pinheiro da Costa BE, Kurlak LO, Broughton Pipkin F, Czajka A, Mistry HD. Placental expression of eNOS, iNOS and the major protein components of caveolae in women with pre-eclampsia. Placenta. 2015;36(5):607–610. [PubMed: 25707739]

231. Khalil RA, Crews JK, Novak J, Kassab S, Granger JP. Enhanced vascular reactivity during inhibition of nitric oxide synthesis in pregnant rats. Hypertension. 1998;31(5):1065–1069. [PubMed: 9576115]

232. Javadian P, Salmanian B, Javadi-Paydar M, Shamshirsaz AA, Ejtemaei Mehr S, Gharedaghi MH, Dehpour AR. Effect of morphine on the reduced uteroplacental perfusion model of pre-eclampsia in rats. European journal of obstetrics, gynecology, and reproductive biology. 2013;168(2):161–166.

233. Alexander BT, Llinas MT, Kruckeberg WC, Granger JP. L-arginine attenuates hypertension in pregnant rats with reduced uterine perfusion pressure. Hypertension. 2004;43(4):832–836. [PubMed: 14769812]

234. Suzuki Y, Hattori T, Kajikuri J, Yamamoto T, Suzumori K, Itoh T. Reduced function of endothelial prostacyclin in human omental resistance arteries in pre-eclampsia. J Physiol. 2002;545(Pt 1):269–277. [PubMed: 12042358]

235. Majed BH, Khalil RA. Molecular mechanisms regulating the vascular prostacyclin pathways and their adaptation during pregnancy and in the newborn. Pharmacol Rev. 2012;64(3):540–582. [PubMed: 22679221]

236. Bowen RS, Zhang Y, Gu Y, Lewis DF, Wang Y. Increased phospholipase A2 and thromboxane but not prostacyclin production by placental trophoblast cells from normal and preeclamptic pregnancies cultured under hypoxia condition. Placenta. 2005;26(5):402–409. [PubMed: 15850645]

237. Zhao S, Gu Y, Lewis DF, Wang Y. Predominant basal directional release of thromboxane, but not prostacyclin, by placental trophoblasts from normal and preeclamptic pregnancies. Placenta. 2008;29(1):81–88. [PubMed: 17936899]

238. Wang K, Ahmad S, Cai M, Rennie J, Fujisawa T, Crispi F, Baily J, Miller MR, Cudmore M, Hadoke PW, Wang R, Gratacos E, Buhimschi IA, Buhimschi CS, Ahmed A. Dysregulation of hydrogen sulfide producing enzyme cystathionine gamma-lyase contributes to maternal hypertension and placental abnormalities in preeclampsia. Circulation. 2013;127(25):2514–2522. [PubMed: 23704251]

239. Coleman HA, Tare M, Parkington HC. Endothelial potassium channels, endothelium-dependent hyperpolarization and the regulation of vascular tone in health and disease. Clinical and experimental pharmacology & physiology. 2004;31(9):641–649. [PubMed: 15479173]

240. Shimokawa H Hydrogen peroxide as an endothelium-derived hyperpolarizing factor. Pflugers Archiv : European journal of physiology. 2010;459(6):915–922. [PubMed: 20140449]

241. Feletou M, Vanhoutte PM. EDHF: an update. Clinical science. 2009;117(4):139–155. [PubMed: 19601928]

242. Luksha L, Nisell H, Kublickiene K. The mechanism of EDHF-mediated responses in subcutaneous small arteries from healthy pregnant women. American journal of physiology. Regulatory, integrative and comparative physiology. 2004;286(6):R1102–1109.

243. Kenny LC, Baker PN, Kendall DA, Randall MD, Dunn WR. Differential mechanisms of endothelium-dependent vasodilator responses in human myometrial small arteries in normal pregnancy and pre-eclampsia. Clinical science. 2002;103(1):67–73. [PubMed: 12095405]

244. Hammond S, Mathewson AM, Baker PN, Mayhew TM, Dunn WR. Gap junctions and hydrogen peroxide are involved in endothelium-derived hyperpolarising responses to bradykinin in omental arteries and veins isolated from pregnant women. European journal of pharmacology. 2011;668(1–2):225–232. [PubMed: 21762687]

245. Gokina NI, Kuzina OY, Vance AM. Augmented EDHF signaling in rat uteroplacental vasculature during late pregnancy. American journal of physiology. Heart and circulatory physiology. 2010;299(5):H1642–1652. [PubMed: 20817830]

246. Fulep EE, Vedernikov YP, Saade GR, Garfield RE. The role of endothelium-derived hyperpolarizing factor in the regulation of the uterine circulation in pregnant rats. American journal of obstetrics and gynecology. 2001;185(3):638–642. [PubMed: 11568792]

247. Luksha L, Nisell H, Luksha N, Kublickas M, Hultenby K, Kublickiene K. Endothelium-derived hyperpolarizing factor in preeclampsia: heterogeneous contribution, mechanisms, and morphological prerequisites. American journal of physiology. Regulatory, integrative and comparative physiology. 2008;294(2):R510–519.

248. Luksha L, Luksha N, Kublickas M, Nisell H, Kublickiene K. Diverse mechanisms of endothelium-derived hyperpolarizing factor-mediated dilatation in small myometrial arteries in normal human pregnancy and preeclampsia. Biology of reproduction. 2010;83(5):728–735. [PubMed: 20610807]

249. Hagedorn KA, Cooke CL, Falck JR, Mitchell BF, Davidge ST. Regulation of vascular tone during pregnancy: a novel role for the pregnane X receptor. Hypertension. 2007;49(2):328–333. [PubMed: 17159084]

250. George EM, Granger JP. Endothelin: key mediator of hypertension in preeclampsia. American journal of hypertension. 2011;24(9):964–969. [PubMed: 21677700]

251. Scalera F, Schlembach D, Beinder E. Production of vasoactive substances by human umbilical vein endothelial cells after incubation with serum from preeclamptic patients. European journal of obstetrics, gynecology, and reproductive biology. 2001;99(2):172–178.

252. Roberts JM. Endothelial dysfunction in preeclampsia. Seminars in reproductive endocrinology. 1998;16(1):5–15. [PubMed: 9654603]

253. Taylor RN, Varma M, Teng NN, Roberts JM. Women with preeclampsia have higher plasma endothelin levels than women with normal pregnancies. The Journal of clinical endocrinology and metabolism. 1990;71(6):1675–1677. [PubMed: 2229324]

254. Naiker S, Naidoo S, Naicker T, Gathiram P, Nadar A, Moodley J. Immunolocalisation and endothelin-1 values In pre-eclampsia: an immunocytochemical study. Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology. 2001;21(1):39–45. [PubMed: 12521910]

255. Karakus S, Bozoklu Akkar O, Yildiz C, Sancakdar E, Cetin M, Cetin A. Serum levels of ET-1, M30, and angiopoietins-1 and −2 in HELLP syndrome and preeclampsia compared to controls. Archives of gynecology and obstetrics. 2016;293(2):351–359. [PubMed: 26138305]

256. Kourembanas S, McQuillan LP, Leung GK, Faller DV. Nitric oxide regulates the expression of vasoconstrictors and growth factors by vascular endothelium under both normoxia and hypoxia. The Journal of clinical investigation. 1993;92(1):99–104. [PubMed: 8326022]

257. Jain A, Schneider H, Aliyev E, Soydemir F, Baumann M, Surbek D, Hediger M, Brownbill P, Albrecht C. Hypoxic treatment of human dual placental perfusion induces a preeclampsia-like inflammatory response. Lab Invest. 2014;94(8):873–880. [PubMed: 24933425]

258. Alexander BT, Rinewalt AN, Cockrell KL, Massey MB, Bennett WA, Granger JP. Endothelin type a receptor blockade attenuates the hypertension in response to chronic reductions in uterine perfusion pressure. Hypertension. 2001;37(2 Pt 2):485–489.

259. Johnson AC, Tremble SM, Chan SL, Moseley J, LaMarca B, Nagle KJ, Cipolla MJ. Magnesium sulfate treatment reverses seizure susceptibility and decreases neuroinflammation in a rat model of severe preeclampsia. PloS one. 2014;9(11):e113670. [PubMed: 25409522]

260. Fiore G, Florio P, Micheli L, Nencini C, Rossi M, Cerretani D, Ambrosini G, Giorgi G, Petraglia F. Endothelin-1 triggers placental oxidative stress pathways: putative role in preeclampsia. The Journal of clinical endocrinology and metabolism. 2005;90(7):4205–4210. [PubMed: 15840756]

261. Mazzuca MQ, Khalil RA. Vascular endothelin receptor type B: structure, function and dysregulation in vascular disease. Biochemical pharmacology. 2012;84(2):147–162. [PubMed: 22484314]

262. Seo B, Oemar BS, Siebenmann R, von Segesser L, Luscher TF. Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels. Circulation. 1994;89(3):1203–1208. [PubMed: 8124808]

263. Pollock DM, Keith TL, Highsmith RF. Endothelin receptors and calcium signaling. FASEB J. 1995;9(12):1196–1204. [PubMed: 7672512]

264. Mazzuca MQ, Dang Y, Khalil RA. Enhanced endothelin receptor type B-mediated vasodilation and underlying $[Ca(2)(+)]i$ in mesenteric microvessels of pregnant rats. British journal of pharmacology. 2013;169(6):1335–1351. [PubMed: 23646960]

265. Ou M, Dang Y, Mazzuca MQ, Basile R, Khalil RA. Adaptive regulation of endothelin receptor type-A and type-B in vascular smooth muscle cells during pregnancy in rats. Journal of cellular physiology. 2014;229(4):489–501. [PubMed: 24105843]

266. LaMarca BB, Cockrell K, Sullivan E, Bennett W, Granger JP. Role of endothelin in mediating tumor necrosis factor-induced hypertension in pregnant rats. Hypertension. 2005;46(1):82–86. [PubMed: 15928030]

267. Murphy SR, LaMarca BB, Cockrell K, Granger JP. Role of endothelin in mediating soluble fms-like tyrosine kinase 1-induced hypertension in pregnant rats. Hypertension. 2010;55(2):394–398. [PubMed: 20026766]

268. Velloso EP, Pimentel RL, Braga JF, Cabral AC, Reis ZS, Bader M, Santos RA, Wallukat G. Identification of a Novel Agonist-Like Autoantibody in Preeclamptic Patients. American journal of hypertension. 2016;29(3):405–412. [PubMed: 26158852]

269. Conrad KP, Gandley RE, Ogawa T, Nakanishi S, Danielson LA. Endothelin mediates renal vasodilation and hyperfiltration during pregnancy in chronically instrumented conscious rats. The American journal of physiology. 1999;276(5 Pt 2):F767–776. [PubMed: 10330059]

270. Sheppard SJ, Khalil RA. Risk factors and mediators of the vascular dysfunction associated with hypertension in pregnancy. Cardiovasc Hematol Disord Drug Targets. 2010;10(1):33–52. [PubMed: 20041838]

271. Seki H, Kuromaki K, Takeda S, Kinoshita K, Satoh K. Trial of prophylactic administration of TXA2 synthetase inhibitor, ozagrel hydrochloride, for preeclampsia. Hypertens Pregnancy. 1999;18(2):157–164. [PubMed: 10476617]

272. Xiao D, Zhu R, Zhang L. Gestational hypoxia up-regulates protein kinase C and inhibits calcium-activated potassium channels in ovine uterine arteries. Int J Med Sci. 2014;11(9):886–892. [PubMed: 25013368]

273. Wimalasundera RC, Thom SA, Regan L, Hughes AD. Effects of vasoactive agents on intracellular calcium and force in myometrial and subcutaneous resistance arteries isolated from preeclamptic, pregnant, and nonpregnant woman. Am J Obstet Gynecol. 2005;192(2):625–632. [PubMed: 15696013]

274. Murphy JG, Fleming JB, Cockrell KL, Granger JP, Khalil RA. $[Ca(2+)](i)$ signaling in renal arterial smooth muscle cells of pregnant rat is enhanced during inhibition of NOS. Am J Physiol Regul Integr Comp Physiol. 2001;280(1):R87–99. [PubMed: 11124138]

275. Murphy JG, Herrington JN, Granger JP, Khalil RA. Enhanced $[Ca2+]i$ in renal arterial smooth muscle cells of pregnant rats with reduced uterine perfusion pressure. Am J Physiol Heart Circ Physiol. 2003;284(1):H393–403. [PubMed: 12388289]

276. Magness RR, Rosenfeld CR, Carr BR. Protein kinase C in uterine and systemic arteries during ovarian cycle and pregnancy. Am J Physiol. 1991;260(3 Pt 1):E464–470.

277. Kanashiro CA, Cockrell KL, Alexander BT, Granger JP, Khalil RA. Pregnancy-associated reduction in vascular protein kinase C activity rebounds during inhibition of NO synthesis. Am J Physiol Regul Integr Comp Physiol. 2000;278(2):R295–303. [PubMed: 10666128]

278. Farley DB, Ford SP. Evidence for declining extracellular calcium uptake and protein kinase C activity in uterine arterial smooth muscle during gestation in gilts. Biol Reprod. 1992;46(3):315–321. [PubMed: 1319752]

279. Kanashiro CA, Alexander BT, Granger JP, Khalil RA. Ca(2+)-insensitive vascular protein kinase C during pregnancy and NOS inhibition. Hypertension. 1999;34(4 Pt 2):924–930.

280. Wallukat G, Homuth V, Fischer T, Lindschau C, Horstkamp B, Jupner A, Baur E, Nissen E, Vetter K, Neichel D, Dudenhausen JW, Haller H, Luft FC. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest. 1999;103(7):945–952. [PubMed: 10194466]

281. Goulopoulou S, Hannan JL, Matsumoto T, Webb RC. Pregnancy reduces RhoA/Rho kinase and protein kinase C signaling pathways downstream of thromboxane receptor activation in the rat uterine artery. Am J Physiol Heart Circ Physiol. 2012;302(12):H2477–2488. [PubMed: 22542618]

282. Castro MM, Cena J, Cho WJ, Walsh MP, Schulz R. Matrix metalloproteinase-2 proteolysis of calponin-1 contributes to vascular hypocontractility in endotoxemic rats. Arteriosclerosis, thrombosis, and vascular biology. 2012;32(3):662–668.

283. Kyaw M, Yoshizumi M, Tsuchiya K, Izawa Y, Kanematsu Y, Tamaki T. Atheroprotective effects of antioxidants through inhibition of mitogen-activated protein kinases. Acta Pharmacol Sin. 2004;25(8):977–985. [PubMed: 15301727]

284. Ark M, Yilmaz N, Yazici G, Kubat H, Aktas S. Rho-associated protein kinase II (rock II) expression in normal and preeclamptic human placentas. Placenta. 2005;26(1):81–84. [PubMed: 15664415]

285. VanWijk MJ, Boer K, van der Meulen ET, Bleker OP, Spaan JA, VanBavel E. Resistance artery smooth muscle function in pregnancy and preeclampsia. Am J Obstet Gynecol. 2002;186(1):148–154. [PubMed: 11810101]

286. Kataoka C, Egashira K, Inoue S, Takemoto M, Ni W, Koyanagi M, Kitamoto S, Usui M, Kaibuchi K, Shimokawa H, Takeshita A. Important role of Rho-kinase in the pathogenesis of cardiovascular inflammation and remodeling induced by long-term blockade of nitric oxide synthesis in rats. Hypertension. 2002;39(2):245–250. [PubMed: 11847192]

287. Nguyen H, Chiasson VL, Chatterjee P, Kopriva SE, Young KJ, Mitchell BM. Interleukin-17 causes Rho-kinase-mediated endothelial dysfunction and hypertension. Cardiovasc Res. 2013;97(4):696–704. [PubMed: 23263331]

288. Friel AM, Sexton DJ, O'Reilly MW, Smith TJ, Morrison JJ. Rho A/Rho kinase: human umbilical artery mRNA expression in normal and pre eclamptic pregnancies and functional role in isoprostane-induced vasoconstriction. Reproduction. 2006;132(1):169–176. [PubMed: 16816342]

289. Ergul A, Portik-Dobos V, Hutchinson J, Franco J, Anstadt MP. Downregulation of vascular matrix metalloproteinase inducer and activator proteins in hypertensive patients. Am J Hypertens. 2004;17(9):775–782. [PubMed: 15363819]

290. Gelse K, Poschl E, Aigner T. Collagens--structure, function, and biosynthesis. Adv Drug Deliv Rev. 2003;55(12):1531–1546. [PubMed: 14623400]

291. Kucukguven A, Khalil RA. Matrix metalloproteinases as potential targets in the venous dilation associated with varicose veins. Curr Drug Targets. 2013;14(3):287–324. [PubMed: 23316963]

292. Yin Z, Sada AA, Reslan OM, Narula N, Khalil RA. Increased MMPs expression and decreased contraction in the rat myometrium during pregnancy and in response to prolonged stretch and sex hormones. American journal of physiology. Endocrinology and metabolism. 2012;303(1):E55–70. [PubMed: 22496348]

293. Raffetto JD, Ross RL, Khalil RA. Matrix metalloproteinase 2-induced venous dilation via hyperpolarization and activation of K+ channels: relevance to varicose vein formation. Journal of vascular surgery. 2007;45(2):373–380. [PubMed: 17264019]

294. Chew DK, Conte MS, Khalil RA. Matrix metalloproteinase-specific inhibition of Ca2+ entry mechanisms of vascular contraction. Journal of vascular surgery. 2004;40(5):1001–1010. [PubMed: 15557917]

295. Raffetto JD, Barros YV, Wells AK, Khalil RA. MMP-2 induced vein relaxation via inhibition of [Ca2+]e-dependent mechanisms of venous smooth muscle contraction. Role of RGD peptides. J Surg Res. 2010;159(2):755–764. [PubMed: 19482300]

296. Abdalvand A, Morton JS, Bourque SL, Quon AL, Davidge ST. Matrix metalloproteinase enhances big-endothelin-1 constriction in mesenteric vessels of pregnant rats with reduced uterine blood flow. Hypertension. 2013;61(2):488–493. [PubMed: 23297376]

297. Tam Tam KB, George E, Cockrell K, Arany M, Speed J, Martin JN Jr., Lamarca B, Granger JP. Endothelin type A receptor antagonist attenuates placental ischemia-induced hypertension and uterine vascular resistance. American journal of obstetrics and gynecology. 2011;204(4):330 e331–334. [PubMed: 21458623]

298. Schiffrin EL. Endothelin and endothelin antagonists in hypertension. J Hypertens. 1998;16(12 Pt 2):1891–1895.

299. LaMarca BD, Alexander BT, Gilbert JS, Ryan MJ, Sedeek M, Murphy SR, Granger JP. Pathophysiology of hypertension in response to placental ischemia during pregnancy: a central role for endothelin? Gend Med. 2008;5 Suppl A:S133–138. [PubMed: 18395679]

300. Neylon CB. Vascular biology of endothelin signal transduction. Clin Exp Pharmacol Physiol. 1999;26(2):149–153. [PubMed: 10065337]

301. Smith L, Payne JA, Sedeek MH, Granger JP, Khalil RA. Endothelin-induced increases in Ca2+ entry mechanisms of vascular contraction are enhanced during high-salt diet. Hypertension. 2003;41(3 Pt 2):787–793. [PubMed: 14638627]

302. Shimokawa H, Takeshita A. Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol. 2005;25(9):1767–1775. [PubMed: 16002741]

303. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. *Lancet.* 2005;365(9461):785–799. [PubMed: 15733721]

304. Hunt BJ, Missfelder-Lobos H, Parra-Cordero M, Fletcher O, Parmar K, Lefkou E, Lees CC. Pregnancy outcome and fibrinolytic, endothelial and coagulation markers in women undergoing uterine artery Doppler screening at 23 weeks. J Thromb Haemost. 2009;7(6):955–961. [PubMed: 19320824]

305. Herraiz I, Simon E, Gomez-Arriaga PI, Martinez-Moratalla JM, Garcia-Burguillo A, Jimenez EA, Galindo A. Angiogenesis-Related Biomarkers (sFlt-1/PLGF) in the Prediction and Diagnosis of Placental Dysfunction: An Approach for Clinical Integration. Int J Mol Sci. 2015;16(8):19009–19026. [PubMed: 26287164]

306. Liu Y, Zhao Y, Yu A, Zhao B, Gao Y, Niu H. Diagnostic accuracy of the soluble Fms-like tyrosine kinase-1/placental growth factor ratio for preeclampsia: a meta-analysis based on 20 studies. Archives of gynecology and obstetrics. 2015;292(3):507–518. [PubMed: 25716670]

307. Sela S, Itin A, Natanson-Yaron S, Greenfield C, Goldman-Wohl D, Yagel S, Keshet E. A novel human-specific soluble vascular endothelial growth factor receptor 1: cell-type-specific splicing and implications to vascular endothelial growth factor homeostasis and preeclampsia. Circulation research. 2008;102(12):1566–1574. [PubMed: 18515749]

308. Ward K Searching for genetic factors underlying pre-eclampsia: recent progress and persistent challenges. Minerva Ginecol. 2008;60(5):399–419. [PubMed: 18854807]

309. Hamai Y, Fujii T, Yamashita T, Nishina H, Kozuma S, Mikami Y, Taketani Y. Evidence for an elevation in serum interleukin-2 and tumor necrosis factor-alpha levels before the clinical manifestations of preeclampsia. American journal of reproductive immunology. 1997;38(2):89–93. [PubMed: 9272206]

310. Gomaa MF, Naguib AH, Swedan KH, Abdellatif SS. Serum tumor necrosis factor-alpha level and uterine artery Doppler indices at 11–13 weeks' gestation for preeclampsia screening in low-risk pregnancies: a prospective observational study. J Reprod Immunol. 2015;109:31–35. [PubMed: 25881914]

311. Perucci LO, Gomes KB, Freitas LG, Godoi LC, Alpoim PN, Pinheiro MB, Miranda AS, Teixeira AL, Dusse LM, Sousa LP. Soluble endoglin, transforming growth factor-Beta 1 and soluble

tumor necrosis factor alpha receptors in different clinical manifestations of preeclampsia. PloS one. 2014;9(5):e97632. [PubMed: 24851923]

312. Serin IS, Ozcelik B, Basbug M, Kilic H, Okur D, Erez R. Predictive value of tumor necrosis factor alpha (TNF-alpha) in preeclampsia. European journal of obstetrics, gynecology, and reproductive biology. 2002;100(2):143–145.

313. Bainbridge SA, Roberts JM, von Versen-Hoynck F, Koch J, Edmunds L, Hubel CA. Uric acid attenuates trophoblast invasion and integration into endothelial cell monolayers. Am J Physiol Cell Physiol. 2009;297(2):C440–450. [PubMed: 19535510]

314. Helmo FR, Lopes AMM, Carneiro A, Campos CG, Silva PB, Dos Reis Monteiro MLG, Rocha LP, Dos Reis MA, Etchebehere RM, Machado JR, Correa RRM. Angiogenic and antiangiogenic factors in preeclampsia. Pathol Res Pract. 2018;214(1):7–14. [PubMed: 29174227]

315. Odibo AO, Zhong Y, Goetzinger KR, Odibo L, Bick JL, Bower CR, Nelson DM. First-trimester placental protein 13, PAPP-A, uterine artery Doppler and maternal characteristics in the prediction of pre-eclampsia. Placenta. 2011;32(8):598–602. [PubMed: 21652068]

316. Reddy A, Suri S, Sargent IL, Redman CW, Muttukrishna S. Maternal circulating levels of activin A, inhibin A, sFlt-1 and endoglin at parturition in normal pregnancy and pre-eclampsia. PloS one. 2009;4(2):e4453. [PubMed: 19412349]

317. Kim SY, Ryu HM, Yang JH, Kim MY, Ahn HK, Shin JS, Choi JS, Park SY, Kim JM, Lee BY, Kim DJ. Maternal serum and amniotic fluid inhibin A levels in women who subsequently develop severe preeclampsia. J Korean Med Sci. 2006;21(3):452–456. [PubMed: 16778388]

318. Staff AC, Braekke K, Harsem NK, Lyberg T, Holthe MR. Circulating concentrations of sFlt1 (soluble fms-like tyrosine kinase 1) in fetal and maternal serum during pre-eclampsia. Eur J Obstet Gynecol Reprod Biol. 2005;122(1):33–39. [PubMed: 15935542]

319. Purwosunu Y, Sekizawa A, Okazaki S, Farina A, Wibowo N, Nakamura M, Rizzo N, Saito H, Okai T. Prediction of preeclampsia by analysis of cell-free messenger RNA in maternal plasma. Am J Obstet Gynecol. 2009;200(4):386 e381–387. [PubMed: 19217595]

320. Akehurst C, Small HY, Sharafetdinova L, Forrest R, Beattie W, Brown CE, Robinson SW, McClure JD, Work LM, Carty DM, McBride MW, Freeman DJ, Delles C. Differential expression of microRNA-206 and its target genes in preeclampsia. Journal of hypertension. 2015;33(10): 2068–2074. [PubMed: 26213997]

321. Luque A, Farwati A, Crovetto F, Crispi F, Figueras F, Gratacos E, Aran JM. Usefulness of circulating microRNAs for the prediction of early preeclampsia at first-trimester of pregnancy. Sci Rep. 2014;4:4882. [PubMed: 24811064]

322. Kanasaki K, Palmsten K, Sugimoto H, Ahmad S, Hamano Y, Xie L, Parry S, Augustin HG, Gattone VH, Folkman J, Strauss JF, Kalluri R. Deficiency in catechol-O-methyltransferase and 2-methoxyoestradiol is associated with pre-eclampsia. Nature. 2008;453(7198):1117–1121. [PubMed: 18469803]

323. Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. Pregnancy hypertension. 2014;4(2):105–145. [PubMed: 26104418]

324. McDonald SD, Lutsiv O, Dzaja N, Duley L. A systematic review of maternal and infant outcomes following magnesium sulfate for pre-eclampsia/eclampsia in real-world use. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2012;118(2):90–96.

325. von Dadelszen P, Dwinnell S, Magee LA, Carleton BC, Gruslin A, Lee B, Lim KI, Liston RM, Miller SP, Rurak D, Sherlock RL, Skoll MA, Wareing MM, Baker PN. Sildenafil citrate therapy for severe early-onset intrauterine growth restriction. BJOG. 2011;118(5):624–628. [PubMed: 21392225]

326. Motta C, Grosso C, Zanuzzi C, Molinero D, Picco N, Bellingeri R, Alustiza F, Barbeito C, Vivas A, Romanini MC. Effect of Sildenafil on Pre-Eclampsia-Like Mouse Model Induced By L-Name. Reprod Domest Anim. 2015;50(4):611–616. [PubMed: 25959785]

327. Burwick RM, Feinberg BB. Eculizumab for the treatment of preeclampsia/HELLP syndrome. Placenta. 2013;34(2):201–203. [PubMed: 23228435]

328. Zhao Y, Zheng YF, Luo QQ, Yan T, Liu XX, Han L, Zou L. Edaravone inhibits hypoxia-induced trophoblast-soluble Fms-like tyrosine kinase 1 expression: a possible therapeutic approach to preeclampsia. Placenta. 2014;35(7):476–482. [PubMed: 24840734]

329. Yinon Y, Ben Meir E, Margolis L, Lipitz S, Schiff E, Mazaki-Tovi S, Simchen MJ. Low molecular weight heparin therapy during pregnancy is associated with elevated circulatory levels of placental growth factor. Placenta. 2015;36(2):121–124. [PubMed: 25555501]

330. Spradley FT, Tan AY, Joo WS, Daniels G, Kussie P, Karumanchi SA, Granger JP. Placental Growth Factor Administration Abolishes Placental Ischemia-Induced Hypertension. Hypertension. 2016;67(4):740–747. [PubMed: 26831193]

331. Gutkowska J, Granger JP, Lamarca BB, Danalache BA, Wang D, Jankowski M. Changes in cardiac structure in hypertension produced by placental ischemia in pregnant rats: effect of tumor necrosis factor blockade. Journal of hypertension. 2011;29(6):1203–1212. [PubMed: 21505354]

332. Cornelius DC, Hogg JP, Scott J, Wallace K, Herse F, Moseley J, Wallukat G, Dechend R, LaMarca B. Administration of interleukin-17 soluble receptor C suppresses TH17 cells, oxidative stress, and hypertension in response to placental ischemia during pregnancy. Hypertension. 2013;62(6):1068–1073. [PubMed: 24060899]

333. Tinsley JH, South S, Chiasson VL, Mitchell BM. Interleukin-10 reduces inflammation, endothelial dysfunction, and blood pressure in hypertensive pregnant rats. Am J Physiol Regul Integr Comp Physiol. 2010;298(3):R713–719. [PubMed: 20053959]

334. Awad AE, Kandalam V, Chakrabarti S, Wang X, Penninger JM, Davidge ST, Oudit GY, Kassiri Z. Tumor necrosis factor induces matrix metalloproteinases in cardiomyocytes and cardiofibroblasts differentially via superoxide production in a PI3Kgamma-dependent manner. Am J Physiol Cell Physiol. 2010;298(3):C679–692. [PubMed: 20007453]

Genetic and Environmental Predisposing Factors

Defective Placentation

Cytokines Integrins MMPs

Reduced Uteroplacental Perfusion Pressure (RUPP)
Uteroplacental Ischemia

Circulating Bioactive Factors

| ↑ | sFlt-1 | sEng | TNFα, IL-6 | ROS | HIF | AT1-AA |
| ↓ | VEGF, PlGF | TGF-β | IL-10 | HO | | |

Vascular Targets

Endothelium

ET$_{1-32}$
ET$_B$R
VSM
ET-1
ET$_A$R
MMPs
ECM

↓ NO PGI$_2$ EDHF

↑ Ca^{2+} PKC ROCK

↑ Collagen

↓ Vasodilation   ↑ Vasoconstriction   ↓ Vascular Remodeling

Hypertension in Pregnancy

Fig. 1.

Mechanisms of microvascular dysfunction in HTN-Preg. Initial reduction of uteroplacental perfusion pressure (RUPP) and uteroplacental ischemia causes the release of bioactive and circulating factors, which target blood vessels leading to decreased endothelium-dependent vascular relaxation pathways, increased endothelin-1 (ET-1) and mechanisms of VSM contraction, and abnormalities in MMPs expression/activity and increased collagen deposition in extracellular matrix (ECM), resulting in increased vascular resistance and HTN-Preg.

AT$_1$-AA, AngII AT$_1$R agonistic autoantibodies; EDHF, endothelium-derived hyperpolarizing factor; HIF, hypoxia-inducible factor; HO, hemeoxygenase, IL-6, interleukin-6; NO, nitric oxide; PKC, protein kinase C; PlGF, placental growth factor; ROS, reactive oxygen species; sEng, soluble endoglin; sFlt-1, soluble fms-like tyrosine kinase-1; TNFα, tumor necrosis factor-α; VEGF, vascular endothelial growth factor; VSM, vascular smooth muscle